#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Neuron-specific signatures in the chromosomal connectome associated with schizophrenia risk To explore the developmental reorganization of the three-dimensional genome of the brain in the context of neuropsychiatric disease, we monitored chromosomal conformations in differentiating neural progenitor cells.
1-1	0-15	Neuron-specific	_
1-2	16-26	signatures	_
1-3	27-29	in	_
1-4	30-33	the	_
1-5	34-45	chromosomal	_
1-6	46-56	connectome	_
1-7	57-67	associated	_
1-8	68-72	with	_
1-9	73-86	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	87-91	risk	_
1-11	92-94	To	_
1-12	95-102	explore	_
1-13	103-106	the	_
1-14	107-120	developmental	_
1-15	121-135	reorganization	_
1-16	136-138	of	_
1-17	139-142	the	_
1-18	143-160	three-dimensional	_
1-19	161-167	genome	_
1-20	168-170	of	_
1-21	171-174	the	_
1-22	175-180	brain	_
1-23	181-183	in	_
1-24	184-187	the	_
1-25	188-195	context	_
1-26	196-198	of	_
1-27	199-215	neuropsychiatric	_
1-28	216-223	disease	_
1-29	224-225	,	_
1-30	226-228	we	_
1-31	229-238	monitored	_
1-32	239-250	chromosomal	_
1-33	251-264	conformations	_
1-34	265-267	in	_
1-35	268-283	differentiating	_
1-36	284-290	neural	_
1-37	291-301	progenitor	_
1-38	302-307	cells	_
1-39	308-309	.	_

Text=Neuronal and glial differentiation was associated with widespread developmental remodeling of the chromosomal contact map and included interactions anchored in common variant sequences that confer heritable risk for schizophrenia.
2-1	310-318	Neuronal	_
2-2	319-322	and	_
2-3	323-328	glial	_
2-4	329-344	differentiation	_
2-5	345-348	was	_
2-6	349-359	associated	_
2-7	360-364	with	_
2-8	365-375	widespread	_
2-9	376-389	developmental	_
2-10	390-400	remodeling	_
2-11	401-403	of	_
2-12	404-407	the	_
2-13	408-419	chromosomal	_
2-14	420-427	contact	_
2-15	428-431	map	_
2-16	432-435	and	_
2-17	436-444	included	_
2-18	445-457	interactions	_
2-19	458-466	anchored	_
2-20	467-469	in	_
2-21	470-476	common	_
2-22	477-484	variant	_
2-23	485-494	sequences	_
2-24	495-499	that	_
2-25	500-506	confer	_
2-26	507-516	heritable	_
2-27	517-521	risk	_
2-28	522-525	for	_
2-29	526-539	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-30	540-541	.	_

Text=We describe cell type–specific chromosomal connectomes composed of schizophrenia risk variants and their distal targets, which altogether show enrichment for genes that regulate neuronal connectivity and chromatin remodeling, and evidence for coordinated transcriptional regulation and proteomic interaction of the participating genes.
3-1	542-544	We	_
3-2	545-553	describe	_
3-3	554-558	cell	_
3-4	559-572	type–specific	_
3-5	573-584	chromosomal	_
3-6	585-596	connectomes	_
3-7	597-605	composed	_
3-8	606-608	of	_
3-9	609-622	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-10	623-627	risk	_
3-11	628-636	variants	_
3-12	637-640	and	_
3-13	641-646	their	_
3-14	647-653	distal	_
3-15	654-661	targets	_
3-16	662-663	,	_
3-17	664-669	which	_
3-18	670-680	altogether	_
3-19	681-685	show	_
3-20	686-696	enrichment	_
3-21	697-700	for	_
3-22	701-706	genes	_
3-23	707-711	that	_
3-24	712-720	regulate	_
3-25	721-729	neuronal	_
3-26	730-742	connectivity	_
3-27	743-746	and	_
3-28	747-756	chromatin	_
3-29	757-767	remodeling	_
3-30	768-769	,	_
3-31	770-773	and	_
3-32	774-782	evidence	_
3-33	783-786	for	_
3-34	787-798	coordinated	_
3-35	799-814	transcriptional	_
3-36	815-825	regulation	_
3-37	826-829	and	_
3-38	830-839	proteomic	_
3-39	840-851	interaction	_
3-40	852-854	of	_
3-41	855-858	the	_
3-42	859-872	participating	_
3-43	873-878	genes	_
3-44	879-880	.	_

Text=Developmentally regulated chromosomal conformation changes at schizophrenia-relevant sequences disproportionally occurred in neurons, highlighting the existence of cell type–specific disease risk vulnerabilities in spatial genome organization.
4-1	881-896	Developmentally	_
4-2	897-906	regulated	_
4-3	907-918	chromosomal	_
4-4	919-931	conformation	_
4-5	932-939	changes	_
4-6	940-942	at	_
4-7	943-965	schizophrenia-relevant	_
4-8	966-975	sequences	_
4-9	976-993	disproportionally	_
4-10	994-1002	occurred	_
4-11	1003-1005	in	_
4-12	1006-1013	neurons	_
4-13	1014-1015	,	_
4-14	1016-1028	highlighting	_
4-15	1029-1032	the	_
4-16	1033-1042	existence	_
4-17	1043-1045	of	_
4-18	1046-1050	cell	_
4-19	1051-1064	type–specific	_
4-20	1065-1072	disease	_
4-21	1073-1077	risk	_
4-22	1078-1093	vulnerabilities	_
4-23	1094-1096	in	_
4-24	1097-1104	spatial	_
4-25	1105-1111	genome	_
4-26	1112-1124	organization	_
4-27	1125-1126	.	_

Text=Graphical Abstract INTRODUCTION: Chromosomal conformations, topologically associated chromatin domains (TADs) assembling in nested fashion across hundreds of kilobases, and other “ three-dimensional genome ” (3DG) structures bypass the linear genome on a kilo- or megabase scale and play an important role in transcriptional regulation.
5-1	1127-1136	Graphical	_
5-2	1137-1145	Abstract	_
5-3	1146-1158	INTRODUCTION	_
5-4	1159-1160	:	_
5-5	1161-1172	Chromosomal	_
5-6	1173-1186	conformations	_
5-7	1187-1188	,	_
5-8	1189-1202	topologically	_
5-9	1203-1213	associated	_
5-10	1214-1223	chromatin	_
5-11	1224-1231	domains	_
5-12	1232-1233	(	_
5-13	1234-1238	TADs	_
5-14	1239-1240	)	_
5-15	1241-1251	assembling	_
5-16	1252-1254	in	_
5-17	1255-1261	nested	_
5-18	1262-1269	fashion	_
5-19	1270-1276	across	_
5-20	1277-1285	hundreds	_
5-21	1286-1288	of	_
5-22	1289-1298	kilobases	_
5-23	1299-1300	,	_
5-24	1301-1304	and	_
5-25	1305-1310	other	_
5-26	1311-1312	“	_
5-27	1313-1330	three-dimensional	_
5-28	1331-1337	genome	_
5-29	1338-1339	”	_
5-30	1340-1341	(	_
5-31	1342-1345	3DG	_
5-32	1346-1347	)	_
5-33	1348-1358	structures	_
5-34	1359-1365	bypass	_
5-35	1366-1369	the	_
5-36	1370-1376	linear	_
5-37	1377-1383	genome	_
5-38	1384-1386	on	_
5-39	1387-1388	a	_
5-40	1389-1394	kilo-	_
5-41	1395-1397	or	_
5-42	1398-1406	megabase	_
5-43	1407-1412	scale	_
5-44	1413-1416	and	_
5-45	1417-1421	play	_
5-46	1422-1424	an	_
5-47	1425-1434	important	_
5-48	1435-1439	role	_
5-49	1440-1442	in	_
5-50	1443-1458	transcriptional	_
5-51	1459-1469	regulation	_
5-52	1470-1471	.	_

Text=Most of the genetic variants associated with risk for schizophrenia (SZ) are common and could be located in enhancers, repressors, and other regulatory elements that influence gene expression; however, the role of the brain ’ s 3DG for SZ genetic risk architecture, including developmental and cell type–specific regulation, remains poorly understood.
6-1	1472-1476	Most	_
6-2	1477-1479	of	_
6-3	1480-1483	the	_
6-4	1484-1491	genetic	_
6-5	1492-1500	variants	_
6-6	1501-1511	associated	_
6-7	1512-1516	with	_
6-8	1517-1521	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
6-9	1522-1525	for	_
6-10	1526-1539	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-11	1540-1541	(	_
6-12	1542-1544	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-13	1545-1546	)	_
6-14	1547-1550	are	_
6-15	1551-1557	common	_
6-16	1558-1561	and	_
6-17	1562-1567	could	_
6-18	1568-1570	be	_
6-19	1571-1578	located	_
6-20	1579-1581	in	_
6-21	1582-1591	enhancers	_
6-22	1592-1593	,	_
6-23	1594-1604	repressors	_
6-24	1605-1606	,	_
6-25	1607-1610	and	_
6-26	1611-1616	other	_
6-27	1617-1627	regulatory	_
6-28	1628-1636	elements	_
6-29	1637-1641	that	_
6-30	1642-1651	influence	_
6-31	1652-1656	gene	_
6-32	1657-1667	expression	_
6-33	1668-1669	;	_
6-34	1670-1677	however	_
6-35	1678-1679	,	_
6-36	1680-1683	the	_
6-37	1684-1688	role	_
6-38	1689-1691	of	_
6-39	1692-1695	the	_
6-40	1696-1701	brain	_
6-41	1702-1703	’	_
6-42	1704-1705	s	_
6-43	1706-1709	3DG	_
6-44	1710-1713	for	_
6-45	1714-1716	SZ	_
6-46	1717-1724	genetic	_
6-47	1725-1729	risk	_
6-48	1730-1742	architecture	_
6-49	1743-1744	,	_
6-50	1745-1754	including	_
6-51	1755-1768	developmental	_
6-52	1769-1772	and	_
6-53	1773-1777	cell	_
6-54	1778-1791	type–specific	_
6-55	1792-1802	regulation	_
6-56	1803-1804	,	_
6-57	1805-1812	remains	_
6-58	1813-1819	poorly	_
6-59	1820-1830	understood	_
6-60	1831-1832	.	_

Text=RATIONALE: We monitored changes in 3DG after isogenic differentiation of human induced pluripotent stem cell–derived neural progenitor cells (NPCs) into neurons or astrocyte-like glial cells on a genome-wide scale using Hi-C. With this in vitro model of brain development, we mapped cell type–specific chromosomal conformations associated with SZ risk loci and defined a risk-associated expanded genome space.
7-1	1833-1842	RATIONALE	_
7-2	1843-1844	:	_
7-3	1845-1847	We	_
7-4	1848-1857	monitored	_
7-5	1858-1865	changes	_
7-6	1866-1868	in	_
7-7	1869-1872	3DG	_
7-8	1873-1878	after	_
7-9	1879-1887	isogenic	_
7-10	1888-1903	differentiation	_
7-11	1904-1906	of	_
7-12	1907-1912	human	_
7-13	1913-1920	induced	_
7-14	1921-1932	pluripotent	_
7-15	1933-1937	stem	_
7-16	1938-1950	cell–derived	_
7-17	1951-1957	neural	_
7-18	1958-1968	progenitor	_
7-19	1969-1974	cells	_
7-20	1975-1976	(	_
7-21	1977-1981	NPCs	_
7-22	1982-1983	)	_
7-23	1984-1988	into	_
7-24	1989-1996	neurons	_
7-25	1997-1999	or	_
7-26	2000-2014	astrocyte-like	_
7-27	2015-2020	glial	_
7-28	2021-2026	cells	_
7-29	2027-2029	on	_
7-30	2030-2031	a	_
7-31	2032-2043	genome-wide	_
7-32	2044-2049	scale	_
7-33	2050-2055	using	_
7-34	2056-2061	Hi-C.	_
7-35	2062-2066	With	_
7-36	2067-2071	this	_
7-37	2072-2074	in	_
7-38	2075-2080	vitro	_
7-39	2081-2086	model	_
7-40	2087-2089	of	_
7-41	2090-2095	brain	_
7-42	2096-2107	development	_
7-43	2108-2109	,	_
7-44	2110-2112	we	_
7-45	2113-2119	mapped	_
7-46	2120-2124	cell	_
7-47	2125-2138	type–specific	_
7-48	2139-2150	chromosomal	_
7-49	2151-2164	conformations	_
7-50	2165-2175	associated	_
7-51	2176-2180	with	_
7-52	2181-2183	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
7-53	2184-2188	risk	_
7-54	2189-2193	loci	_
7-55	2194-2197	and	_
7-56	2198-2205	defined	_
7-57	2206-2207	a	_
7-58	2208-2223	risk-associated	_
7-59	2224-2232	expanded	_
7-60	2233-2239	genome	_
7-61	2240-2245	space	_
7-62	2246-2247	.	_

Text=RESULTS: Neural differentiation was associated with genome-wide 3DG remodeling, including pruning and de novo formations of chromosomal loopings.
8-1	2248-2255	RESULTS	_
8-2	2256-2257	:	_
8-3	2258-2264	Neural	_
8-4	2265-2280	differentiation	_
8-5	2281-2284	was	_
8-6	2285-2295	associated	_
8-7	2296-2300	with	_
8-8	2301-2312	genome-wide	_
8-9	2313-2316	3DG	_
8-10	2317-2327	remodeling	_
8-11	2328-2329	,	_
8-12	2330-2339	including	_
8-13	2340-2347	pruning	_
8-14	2348-2351	and	_
8-15	2352-2354	de	_
8-16	2355-2359	novo	_
8-17	2360-2370	formations	_
8-18	2371-2373	of	_
8-19	2374-2385	chromosomal	_
8-20	2386-2394	loopings	_
8-21	2395-2396	.	_

Text=The NPC-to-neuron transition was defined by the pruning of loops involving regulators of cell proliferation, morphogenesis, and neurogenesis, which is consistent with a departure from a precursor stage toward postmitotic neuronal identity.
9-1	2397-2400	The	_
9-2	2401-2414	NPC-to-neuron	_
9-3	2415-2425	transition	_
9-4	2426-2429	was	_
9-5	2430-2437	defined	_
9-6	2438-2440	by	_
9-7	2441-2444	the	_
9-8	2445-2452	pruning	_
9-9	2453-2455	of	_
9-10	2456-2461	loops	_
9-11	2462-2471	involving	_
9-12	2472-2482	regulators	_
9-13	2483-2485	of	_
9-14	2486-2490	cell	_
9-15	2491-2504	proliferation	_
9-16	2505-2506	,	_
9-17	2507-2520	morphogenesis	_
9-18	2521-2522	,	_
9-19	2523-2526	and	_
9-20	2527-2539	neurogenesis	_
9-21	2540-2541	,	_
9-22	2542-2547	which	_
9-23	2548-2550	is	_
9-24	2551-2561	consistent	_
9-25	2562-2566	with	_
9-26	2567-2568	a	_
9-27	2569-2578	departure	_
9-28	2579-2583	from	_
9-29	2584-2585	a	_
9-30	2586-2595	precursor	_
9-31	2596-2601	stage	_
9-32	2602-2608	toward	_
9-33	2609-2620	postmitotic	_
9-34	2621-2629	neuronal	_
9-35	2630-2638	identity	_
9-36	2639-2640	.	_

Text=Loops lost during NPC-to-glia transition included many genes associated with neuron-specific functions, which is consistent with non-neuronal lineage commitment.
10-1	2641-2646	Loops	_
10-2	2647-2651	lost	_
10-3	2652-2658	during	_
10-4	2659-2670	NPC-to-glia	_
10-5	2671-2681	transition	_
10-6	2682-2690	included	_
10-7	2691-2695	many	_
10-8	2696-2701	genes	_
10-9	2702-2712	associated	_
10-10	2713-2717	with	_
10-11	2718-2733	neuron-specific	_
10-12	2734-2743	functions	_
10-13	2744-2745	,	_
10-14	2746-2751	which	_
10-15	2752-2754	is	_
10-16	2755-2765	consistent	_
10-17	2766-2770	with	_
10-18	2771-2783	non-neuronal	_
10-19	2784-2791	lineage	_
10-20	2792-2802	commitment	_
10-21	2803-2804	.	_

Text=However, neurons together with NPCs, as compared with glia, harbored a much larger number of chromosomal interactions anchored in common variant sequences associated with SZ risk.
11-1	2805-2812	However	_
11-2	2813-2814	,	_
11-3	2815-2822	neurons	_
11-4	2823-2831	together	_
11-5	2832-2836	with	_
11-6	2837-2841	NPCs	_
11-7	2842-2843	,	_
11-8	2844-2846	as	_
11-9	2847-2855	compared	_
11-10	2856-2860	with	_
11-11	2861-2865	glia	_
11-12	2866-2867	,	_
11-13	2868-2876	harbored	_
11-14	2877-2878	a	_
11-15	2879-2883	much	_
11-16	2884-2890	larger	_
11-17	2891-2897	number	_
11-18	2898-2900	of	_
11-19	2901-2912	chromosomal	_
11-20	2913-2925	interactions	_
11-21	2926-2934	anchored	_
11-22	2935-2937	in	_
11-23	2938-2944	common	_
11-24	2945-2952	variant	_
11-25	2953-2962	sequences	_
11-26	2963-2973	associated	_
11-27	2974-2978	with	_
11-28	2979-2981	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-29	2982-2986	risk	_
11-30	2987-2988	.	_

Text=Because spatial 3DG proximity of genes is an indicator for potential coregulation, we tested whether the neural cell type–specific SZ-related “ chromosomal connectome ” showed evidence of coordinated transcriptional regulation and proteomic interaction of the participating genes.
12-1	2989-2996	Because	_
12-2	2997-3004	spatial	_
12-3	3005-3008	3DG	_
12-4	3009-3018	proximity	_
12-5	3019-3021	of	_
12-6	3022-3027	genes	_
12-7	3028-3030	is	_
12-8	3031-3033	an	_
12-9	3034-3043	indicator	_
12-10	3044-3047	for	_
12-11	3048-3057	potential	_
12-12	3058-3070	coregulation	_
12-13	3071-3072	,	_
12-14	3073-3075	we	_
12-15	3076-3082	tested	_
12-16	3083-3090	whether	_
12-17	3091-3094	the	_
12-18	3095-3101	neural	_
12-19	3102-3106	cell	_
12-20	3107-3120	type–specific	_
12-21	3121-3131	SZ-related	_
12-22	3132-3133	“	_
12-23	3134-3145	chromosomal	_
12-24	3146-3156	connectome	_
12-25	3157-3158	”	_
12-26	3159-3165	showed	_
12-27	3166-3174	evidence	_
12-28	3175-3177	of	_
12-29	3178-3189	coordinated	_
12-30	3190-3205	transcriptional	_
12-31	3206-3216	regulation	_
12-32	3217-3220	and	_
12-33	3221-3230	proteomic	_
12-34	3231-3242	interaction	_
12-35	3243-3245	of	_
12-36	3246-3249	the	_
12-37	3250-3263	participating	_
12-38	3264-3269	genes	_
12-39	3270-3271	.	_

Text=To this end, we generated lists of genes anchored in cell type–specific SZ risk-associated interactions.
13-1	3272-3274	To	_
13-2	3275-3279	this	_
13-3	3280-3283	end	_
13-4	3284-3285	,	_
13-5	3286-3288	we	_
13-6	3289-3298	generated	_
13-7	3299-3304	lists	_
13-8	3305-3307	of	_
13-9	3308-3313	genes	_
13-10	3314-3322	anchored	_
13-11	3323-3325	in	_
13-12	3326-3330	cell	_
13-13	3331-3344	type–specific	_
13-14	3345-3347	SZ	_
13-15	3348-3363	risk-associated	_
13-16	3364-3376	interactions	_
13-17	3377-3378	.	_

Text=Thus, for the NPC-specific interactions, we counted 386 genes, including 146 within the risk loci and another 240 genes positioned elsewhere in the linear genome but connected via intrachromosomal contacts to risk locus sequences.
14-1	3379-3383	Thus	_
14-2	3384-3385	,	_
14-3	3386-3389	for	_
14-4	3390-3393	the	_
14-5	3394-3406	NPC-specific	_
14-6	3407-3419	interactions	_
14-7	3420-3421	,	_
14-8	3422-3424	we	_
14-9	3425-3432	counted	_
14-10	3433-3436	386	_
14-11	3437-3442	genes	_
14-12	3443-3444	,	_
14-13	3445-3454	including	_
14-14	3455-3458	146	_
14-15	3459-3465	within	_
14-16	3466-3469	the	_
14-17	3470-3474	risk	_
14-18	3475-3479	loci	_
14-19	3480-3483	and	_
14-20	3484-3491	another	_
14-21	3492-3495	240	_
14-22	3496-3501	genes	_
14-23	3502-3512	positioned	_
14-24	3513-3522	elsewhere	_
14-25	3523-3525	in	_
14-26	3526-3529	the	_
14-27	3530-3536	linear	_
14-28	3537-3543	genome	_
14-29	3544-3547	but	_
14-30	3548-3557	connected	_
14-31	3558-3561	via	_
14-32	3562-3578	intrachromosomal	_
14-33	3579-3587	contacts	_
14-34	3588-3590	to	_
14-35	3591-3595	risk	_
14-36	3596-3601	locus	_
14-37	3602-3611	sequences	_
14-38	3612-3613	.	_

Text=Similarly, for the neuron-specific interactions, we identified 385 genes: 158 within risk loci and 227 outside of risk loci.
15-1	3614-3623	Similarly	_
15-2	3624-3625	,	_
15-3	3626-3629	for	_
15-4	3630-3633	the	_
15-5	3634-3649	neuron-specific	_
15-6	3650-3662	interactions	_
15-7	3663-3664	,	_
15-8	3665-3667	we	_
15-9	3668-3678	identified	_
15-10	3679-3682	385	_
15-11	3683-3688	genes	_
15-12	3689-3690	:	_
15-13	3691-3694	158	_
15-14	3695-3701	within	_
15-15	3702-3706	risk	_
15-16	3707-3711	loci	_
15-17	3712-3715	and	_
15-18	3716-3719	227	_
15-19	3720-3727	outside	_
15-20	3728-3730	of	_
15-21	3731-3735	risk	_
15-22	3736-3740	loci	_
15-23	3741-3742	.	_

Text=Last, for glia-specific interactions, we identified 201 genes: 88 within and 113 outside of risk loci.
16-1	3743-3747	Last	_
16-2	3748-3749	,	_
16-3	3750-3753	for	_
16-4	3754-3767	glia-specific	_
16-5	3768-3780	interactions	_
16-6	3781-3782	,	_
16-7	3783-3785	we	_
16-8	3786-3796	identified	_
16-9	3797-3800	201	_
16-10	3801-3806	genes	_
16-11	3807-3808	:	_
16-12	3809-3811	88	_
16-13	3812-3818	within	_
16-14	3819-3822	and	_
16-15	3823-3826	113	_
16-16	3827-3834	outside	_
16-17	3835-3837	of	_
16-18	3838-3842	risk	_
16-19	3843-3847	loci	_
16-20	3848-3849	.	_

Text=We labeled the genes located outside of schizophrenia risk loci as “ risk locus–connect, ” which we define as a collection of genes identified only through Hi-C interaction data, expanding—depending on cell type—by 50 to 150% the current network of known genes overlapping risk sequences that is informed only by genome-wide association studies.
17-1	3850-3852	We	_
17-2	3853-3860	labeled	_
17-3	3861-3864	the	_
17-4	3865-3870	genes	_
17-5	3871-3878	located	_
17-6	3879-3886	outside	_
17-7	3887-3889	of	_
17-8	3890-3903	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-9	3904-3908	risk	_
17-10	3909-3913	loci	_
17-11	3914-3916	as	_
17-12	3917-3918	“	_
17-13	3919-3923	risk	_
17-14	3924-3937	locus–connect	_
17-15	3938-3939	,	_
17-16	3940-3941	”	_
17-17	3942-3947	which	_
17-18	3948-3950	we	_
17-19	3951-3957	define	_
17-20	3958-3960	as	_
17-21	3961-3962	a	_
17-22	3963-3973	collection	_
17-23	3974-3976	of	_
17-24	3977-3982	genes	_
17-25	3983-3993	identified	_
17-26	3994-3998	only	_
17-27	3999-4006	through	_
17-28	4007-4011	Hi-C	_
17-29	4012-4023	interaction	_
17-30	4024-4028	data	_
17-31	4029-4030	,	_
17-32	4031-4050	expanding—depending	_
17-33	4051-4053	on	_
17-34	4054-4058	cell	_
17-35	4059-4066	type—by	_
17-36	4067-4069	50	_
17-37	4070-4072	to	_
17-38	4073-4076	150	_
17-39	4077-4078	%	_
17-40	4079-4082	the	_
17-41	4083-4090	current	_
17-42	4091-4098	network	_
17-43	4099-4101	of	_
17-44	4102-4107	known	_
17-45	4108-4113	genes	_
17-46	4114-4125	overlapping	_
17-47	4126-4130	risk	_
17-48	4131-4140	sequences	_
17-49	4141-4145	that	_
17-50	4146-4148	is	_
17-51	4149-4157	informed	_
17-52	4158-4162	only	_
17-53	4163-4165	by	_
17-54	4166-4177	genome-wide	_
17-55	4178-4189	association	_
17-56	4190-4197	studies	_
17-57	4198-4199	.	_

Text=This disease-related chromosomal connectome was associated with “ clusters ” of coordinated gene expression and protein interactions, with at least one cluster strongly enriched for regulators of neuronal connectivity and synaptic plasticity and another cluster for chromatin-associated proteins, including transcriptional regulators.
18-1	4200-4204	This	_
18-2	4205-4220	disease-related	_
18-3	4221-4232	chromosomal	_
18-4	4233-4243	connectome	_
18-5	4244-4247	was	_
18-6	4248-4258	associated	_
18-7	4259-4263	with	_
18-8	4264-4265	“	_
18-9	4266-4274	clusters	_
18-10	4275-4276	”	_
18-11	4277-4279	of	_
18-12	4280-4291	coordinated	_
18-13	4292-4296	gene	_
18-14	4297-4307	expression	_
18-15	4308-4311	and	_
18-16	4312-4319	protein	_
18-17	4320-4332	interactions	_
18-18	4333-4334	,	_
18-19	4335-4339	with	_
18-20	4340-4342	at	_
18-21	4343-4348	least	_
18-22	4349-4352	one	_
18-23	4353-4360	cluster	_
18-24	4361-4369	strongly	_
18-25	4370-4378	enriched	_
18-26	4379-4382	for	_
18-27	4383-4393	regulators	_
18-28	4394-4396	of	_
18-29	4397-4405	neuronal	_
18-30	4406-4418	connectivity	_
18-31	4419-4422	and	_
18-32	4423-4431	synaptic	_
18-33	4432-4442	plasticity	_
18-34	4443-4446	and	_
18-35	4447-4454	another	_
18-36	4455-4462	cluster	_
18-37	4463-4466	for	_
18-38	4467-4487	chromatin-associated	_
18-39	4488-4496	proteins	_
18-40	4497-4498	,	_
18-41	4499-4508	including	_
18-42	4509-4524	transcriptional	_
18-43	4525-4535	regulators	_
18-44	4536-4537	.	_

Text=CONCLUSION: Our study shows that neural differentiation is associated with highly cell type–specific 3DG remodeling.
19-1	4538-4548	CONCLUSION	_
19-2	4549-4550	:	_
19-3	4551-4554	Our	_
19-4	4555-4560	study	_
19-5	4561-4566	shows	_
19-6	4567-4571	that	_
19-7	4572-4578	neural	_
19-8	4579-4594	differentiation	_
19-9	4595-4597	is	_
19-10	4598-4608	associated	_
19-11	4609-4613	with	_
19-12	4614-4620	highly	_
19-13	4621-4625	cell	_
19-14	4626-4639	type–specific	_
19-15	4640-4643	3DG	_
19-16	4644-4654	remodeling	_
19-17	4655-4656	.	_

Text=This process is paralleled by an expansion of 3DG space associated with SZ risk.
20-1	4657-4661	This	_
20-2	4662-4669	process	_
20-3	4670-4672	is	_
20-4	4673-4683	paralleled	_
20-5	4684-4686	by	_
20-6	4687-4689	an	_
20-7	4690-4699	expansion	_
20-8	4700-4702	of	_
20-9	4703-4706	3DG	_
20-10	4707-4712	space	_
20-11	4713-4723	associated	_
20-12	4724-4728	with	_
20-13	4729-4731	SZ	_
20-14	4732-4736	risk	_
20-15	4737-4738	.	_

Text=Specifically, developmentally regulated chromosomal conformation changes at SZ-relevant sequences disproportionally occurred in neurons, highlighting the existence of cell type–specific disease risk vulnerabilities in spatial genome organization.
21-1	4739-4751	Specifically	_
21-2	4752-4753	,	_
21-3	4754-4769	developmentally	_
21-4	4770-4779	regulated	_
21-5	4780-4791	chromosomal	_
21-6	4792-4804	conformation	_
21-7	4805-4812	changes	_
21-8	4813-4815	at	_
21-9	4816-4827	SZ-relevant	_
21-10	4828-4837	sequences	_
21-11	4838-4855	disproportionally	_
21-12	4856-4864	occurred	_
21-13	4865-4867	in	_
21-14	4868-4875	neurons	_
21-15	4876-4877	,	_
21-16	4878-4890	highlighting	_
21-17	4891-4894	the	_
21-18	4895-4904	existence	_
21-19	4905-4907	of	_
21-20	4908-4912	cell	_
21-21	4913-4926	type–specific	_
21-22	4927-4934	disease	_
21-23	4935-4939	risk	_
21-24	4940-4955	vulnerabilities	_
21-25	4956-4958	in	_
21-26	4959-4966	spatial	_
21-27	4967-4973	genome	_
21-28	4974-4986	organization	_
21-29	4987-4988	.	_

Text=3DG remodeling across neuronal differentiation with parallel expansion of SZ risk space.
22-1	4989-4992	3DG	_
22-2	4993-5003	remodeling	_
22-3	5004-5010	across	_
22-4	5011-5019	neuronal	_
22-5	5020-5035	differentiation	_
22-6	5036-5040	with	_
22-7	5041-5049	parallel	_
22-8	5050-5059	expansion	_
22-9	5060-5062	of	_
22-10	5063-5065	SZ	_
22-11	5066-5070	risk	_
22-12	5071-5076	space	_
22-13	5077-5078	.	_

Text=(Left) Chromatin conformation assays reveal pruning of short-range loops in neurons along with widening of TADs upon differentiation from NPCs.
23-1	5079-5080	(	_
23-2	5081-5085	Left	_
23-3	5086-5087	)	_
23-4	5088-5097	Chromatin	_
23-5	5098-5110	conformation	_
23-6	5111-5117	assays	_
23-7	5118-5124	reveal	_
23-8	5125-5132	pruning	_
23-9	5133-5135	of	_
23-10	5136-5147	short-range	_
23-11	5148-5153	loops	_
23-12	5154-5156	in	_
23-13	5157-5164	neurons	_
23-14	5165-5170	along	_
23-15	5171-5175	with	_
23-16	5176-5184	widening	_
23-17	5185-5187	of	_
23-18	5188-5192	TADs	_
23-19	5193-5197	upon	_
23-20	5198-5213	differentiation	_
23-21	5214-5218	from	_
23-22	5219-5223	NPCs	_
23-23	5224-5225	.	_

Text=(Right) Cell type–specific chromatin interactions, functionally validated with CRISPR assays, expand the network of known risk-associated genes (blue circle), which show evidence for coregulation at the transcriptomic and proteomic levels.
24-1	5226-5227	(	_
24-2	5228-5233	Right	_
24-3	5234-5235	)	_
24-4	5236-5240	Cell	_
24-5	5241-5254	type–specific	_
24-6	5255-5264	chromatin	_
24-7	5265-5277	interactions	_
24-8	5278-5279	,	_
24-9	5280-5292	functionally	_
24-10	5293-5302	validated	_
24-11	5303-5307	with	_
24-12	5308-5314	CRISPR	_
24-13	5315-5321	assays	_
24-14	5322-5323	,	_
24-15	5324-5330	expand	_
24-16	5331-5334	the	_
24-17	5335-5342	network	_
24-18	5343-5345	of	_
24-19	5346-5351	known	_
24-20	5352-5367	risk-associated	_
24-21	5368-5373	genes	_
24-22	5374-5375	(	_
24-23	5376-5380	blue	_
24-24	5381-5387	circle	_
24-25	5388-5389	)	_
24-26	5390-5391	,	_
24-27	5392-5397	which	_
24-28	5398-5402	show	_
24-29	5403-5411	evidence	_
24-30	5412-5415	for	_
24-31	5416-5428	coregulation	_
24-32	5429-5431	at	_
24-33	5432-5435	the	_
24-34	5436-5450	transcriptomic	_
24-35	5451-5454	and	_
24-36	5455-5464	proteomic	_
24-37	5465-5471	levels	_
24-38	5472-5473	.	_

Text=Materials and methods In situ Hi-C from hiPSC-derived cells In situ Hi-C libraries were generated from 2 million to 5 million cultured hiPSC-derived NPCs, glia, and neurons as described in without modifications in the protocol.
25-1	5474-5483	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
25-2	5484-5487	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
25-3	5488-5495	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
25-4	5496-5498	In	_
25-5	5499-5503	situ	_
25-6	5504-5508	Hi-C	_
25-7	5509-5513	from	_
25-8	5514-5527	hiPSC-derived	_
25-9	5528-5533	cells	_
25-10	5534-5536	In	_
25-11	5537-5541	situ	_
25-12	5542-5546	Hi-C	_
25-13	5547-5556	libraries	_
25-14	5557-5561	were	_
25-15	5562-5571	generated	_
25-16	5572-5576	from	_
25-17	5577-5578	2	_
25-18	5579-5586	million	_
25-19	5587-5589	to	_
25-20	5590-5591	5	_
25-21	5592-5599	million	_
25-22	5600-5608	cultured	_
25-23	5609-5622	hiPSC-derived	_
25-24	5623-5627	NPCs	_
25-25	5628-5629	,	_
25-26	5630-5634	glia	_
25-27	5635-5636	,	_
25-28	5637-5640	and	_
25-29	5641-5648	neurons	_
25-30	5649-5651	as	_
25-31	5652-5661	described	_
25-32	5662-5664	in	_
25-33	5665-5672	without	_
25-34	5673-5686	modifications	_
25-35	5687-5689	in	_
25-36	5690-5693	the	_
25-37	5694-5702	protocol	_
25-38	5703-5704	.	_

Text=Briefly, in situ Hi-C consists of 7 steps: (i) crosslinking cells with formaldehyde, (ii) digesting the DNA using a 4-cutter restriction enzyme (e.g., MboI) within intact permeabilized nuclei, (iii) filling in and biotinylating the resulting 5′-overhangs, (iv) ligating the blunt ends, (v) shearing the DNA, (vi) pulling down the biotinylated ligation junctions with streptavidin beads, and (vii) analyzing these fragments using paired end sequencing.
26-1	5705-5712	Briefly	_
26-2	5713-5714	,	_
26-3	5715-5717	in	_
26-4	5718-5722	situ	_
26-5	5723-5727	Hi-C	_
26-6	5728-5736	consists	_
26-7	5737-5739	of	_
26-8	5740-5741	7	_
26-9	5742-5747	steps	_
26-10	5748-5749	:	_
26-11	5750-5751	(	_
26-12	5752-5753	i	_
26-13	5754-5755	)	_
26-14	5756-5768	crosslinking	_
26-15	5769-5774	cells	_
26-16	5775-5779	with	_
26-17	5780-5792	formaldehyde	_
26-18	5793-5794	,	_
26-19	5795-5796	(	_
26-20	5797-5799	ii	_
26-21	5800-5801	)	_
26-22	5802-5811	digesting	_
26-23	5812-5815	the	_
26-24	5816-5819	DNA	_
26-25	5820-5825	using	_
26-26	5826-5827	a	_
26-27	5828-5836	4-cutter	_
26-28	5837-5848	restriction	_
26-29	5849-5855	enzyme	_
26-30	5856-5857	(	_
26-31	5858-5862	e.g.	_
26-32	5863-5864	,	_
26-33	5865-5869	MboI	_
26-34	5870-5871	)	_
26-35	5872-5878	within	_
26-36	5879-5885	intact	_
26-37	5886-5899	permeabilized	_
26-38	5900-5906	nuclei	_
26-39	5907-5908	,	_
26-40	5909-5910	(	_
26-41	5911-5914	iii	_
26-42	5915-5916	)	_
26-43	5917-5924	filling	_
26-44	5925-5927	in	_
26-45	5928-5931	and	_
26-46	5932-5945	biotinylating	_
26-47	5946-5949	the	_
26-48	5950-5959	resulting	_
26-49	5960-5972	5′-overhangs	_
26-50	5973-5974	,	_
26-51	5975-5976	(	_
26-52	5977-5979	iv	_
26-53	5980-5981	)	_
26-54	5982-5990	ligating	_
26-55	5991-5994	the	_
26-56	5995-6000	blunt	_
26-57	6001-6005	ends	_
26-58	6006-6007	,	_
26-59	6008-6009	(	_
26-60	6010-6011	v	_
26-61	6012-6013	)	_
26-62	6014-6022	shearing	_
26-63	6023-6026	the	_
26-64	6027-6030	DNA	_
26-65	6031-6032	,	_
26-66	6033-6034	(	_
26-67	6035-6037	vi	_
26-68	6038-6039	)	_
26-69	6040-6047	pulling	_
26-70	6048-6052	down	_
26-71	6053-6056	the	_
26-72	6057-6069	biotinylated	_
26-73	6070-6078	ligation	_
26-74	6079-6088	junctions	_
26-75	6089-6093	with	_
26-76	6094-6106	streptavidin	_
26-77	6107-6112	beads	_
26-78	6113-6114	,	_
26-79	6115-6118	and	_
26-80	6119-6120	(	_
26-81	6121-6124	vii	_
26-82	6125-6126	)	_
26-83	6127-6136	analyzing	_
26-84	6137-6142	these	_
26-85	6143-6152	fragments	_
26-86	6153-6158	using	_
26-87	6159-6165	paired	_
26-88	6166-6169	end	_
26-89	6170-6180	sequencing	_
26-90	6181-6182	.	_

Text=As quality control (QC) steps, we checked for efficient restriction with an agarose DNA gel and for appropriate size selection in using the Agilent Bioanalyzer after steps (v) and (vi).
27-1	6183-6185	As	_
27-2	6186-6193	quality	_
27-3	6194-6201	control	_
27-4	6202-6203	(	_
27-5	6204-6206	QC	_
27-6	6207-6208	)	_
27-7	6209-6214	steps	_
27-8	6215-6216	,	_
27-9	6217-6219	we	_
27-10	6220-6227	checked	_
27-11	6228-6231	for	_
27-12	6232-6241	efficient	_
27-13	6242-6253	restriction	_
27-14	6254-6258	with	_
27-15	6259-6261	an	_
27-16	6262-6269	agarose	_
27-17	6270-6273	DNA	_
27-18	6274-6277	gel	_
27-19	6278-6281	and	_
27-20	6282-6285	for	_
27-21	6286-6297	appropriate	_
27-22	6298-6302	size	_
27-23	6303-6312	selection	_
27-24	6313-6315	in	_
27-25	6316-6321	using	_
27-26	6322-6325	the	_
27-27	6326-6333	Agilent	_
27-28	6334-6345	Bioanalyzer	_
27-29	6346-6351	after	_
27-30	6352-6357	steps	_
27-31	6358-6359	(	_
27-32	6360-6361	v	_
27-33	6362-6363	)	_
27-34	6364-6367	and	_
27-35	6368-6369	(	_
27-36	6370-6372	vi	_
27-37	6373-6374	)	_
27-38	6375-6376	.	_

Text=For the final QC, we performed superficial sequencing on the Illumina MiSeq (~2–3M reads/sample) to assess quality of the libraries using metrics such as percent of reads passing filter, percent of chimeric reads, and percent of forward-reverse pairs (supplementary materials, table S1).
28-1	6377-6380	For	_
28-2	6381-6384	the	_
28-3	6385-6390	final	_
28-4	6391-6393	QC	_
28-5	6394-6395	,	_
28-6	6396-6398	we	_
28-7	6399-6408	performed	_
28-8	6409-6420	superficial	_
28-9	6421-6431	sequencing	_
28-10	6432-6434	on	_
28-11	6435-6438	the	_
28-12	6439-6447	Illumina	_
28-13	6448-6453	MiSeq	_
28-14	6454-6455	(	_
28-15	6456-6461	~2–3M	_
28-16	6462-6474	reads/sample	_
28-17	6475-6476	)	_
28-18	6477-6479	to	_
28-19	6480-6486	assess	_
28-20	6487-6494	quality	_
28-21	6495-6497	of	_
28-22	6498-6501	the	_
28-23	6502-6511	libraries	_
28-24	6512-6517	using	_
28-25	6518-6525	metrics	_
28-26	6526-6530	such	_
28-27	6531-6533	as	_
28-28	6534-6541	percent	_
28-29	6542-6544	of	_
28-30	6545-6550	reads	_
28-31	6551-6558	passing	_
28-32	6559-6565	filter	_
28-33	6566-6567	,	_
28-34	6568-6575	percent	_
28-35	6576-6578	of	_
28-36	6579-6587	chimeric	_
28-37	6588-6593	reads	_
28-38	6594-6595	,	_
28-39	6596-6599	and	_
28-40	6600-6607	percent	_
28-41	6608-6610	of	_
28-42	6611-6626	forward-reverse	_
28-43	6627-6632	pairs	_
28-44	6633-6634	(	_
28-45	6635-6648	supplementary	_
28-46	6649-6658	materials	_
28-47	6659-6660	,	_
28-48	6661-6666	table	_
28-49	6667-6669	S1	_
28-50	6670-6671	)	_
28-51	6672-6673	.	_

Text=For the forebrain directed differentiation neuronal library from subject S1, the Arima Hi-C kit (Arima Genomics, San Diego) was used according to the manufacturer ’ s instructions.
29-1	6674-6677	For	_
29-2	6678-6681	the	_
29-3	6682-6691	forebrain	_
29-4	6692-6700	directed	_
29-5	6701-6716	differentiation	_
29-6	6717-6725	neuronal	_
29-7	6726-6733	library	_
29-8	6734-6738	from	_
29-9	6739-6746	subject	_
29-10	6747-6749	S1	_
29-11	6750-6751	,	_
29-12	6752-6755	the	_
29-13	6756-6761	Arima	_
29-14	6762-6766	Hi-C	_
29-15	6767-6770	kit	_
29-16	6771-6772	(	_
29-17	6773-6778	Arima	_
29-18	6779-6787	Genomics	_
29-19	6788-6789	,	_
29-20	6790-6793	San	_
29-21	6794-6799	Diego	_
29-22	6800-6801	)	_
29-23	6802-6805	was	_
29-24	6806-6810	used	_
29-25	6811-6820	according	_
29-26	6821-6823	to	_
29-27	6824-6827	the	_
29-28	6828-6840	manufacturer	_
29-29	6841-6842	’	_
29-30	6843-6844	s	_
29-31	6845-6857	instructions	_
29-32	6858-6859	.	_

Text=Hi-C read mapping and matrix generation The Hi-C libraries were sequenced on the Illumina HiSeq1000 platform (125bp paired-end) (New York Genome Center).
30-1	6860-6864	Hi-C	_
30-2	6865-6869	read	_
30-3	6870-6877	mapping	_
30-4	6878-6881	and	_
30-5	6882-6888	matrix	_
30-6	6889-6899	generation	_
30-7	6900-6903	The	_
30-8	6904-6908	Hi-C	_
30-9	6909-6918	libraries	_
30-10	6919-6923	were	_
30-11	6924-6933	sequenced	_
30-12	6934-6936	on	_
30-13	6937-6940	the	_
30-14	6941-6949	Illumina	_
30-15	6950-6959	HiSeq1000	_
30-16	6960-6968	platform	_
30-17	6969-6970	(	_
30-18	6971-6976	125bp	_
30-19	6977-6987	paired-end	_
30-20	6988-6989	)	_
30-21	6990-6991	(	_
30-22	6992-6995	New	_
30-23	6996-7000	York	_
30-24	7001-7007	Genome	_
30-25	7008-7014	Center	_
30-26	7015-7016	)	_
30-27	7017-7018	.	_

Text=Technical replicates of subject S2 NPCs, neurons, and glia were also sequenced to enhance resolution.
31-1	7019-7028	Technical	_
31-2	7029-7039	replicates	_
31-3	7040-7042	of	_
31-4	7043-7050	subject	_
31-5	7051-7053	S2	_
31-6	7054-7058	NPCs	_
31-7	7059-7060	,	_
31-8	7061-7068	neurons	_
31-9	7069-7070	,	_
31-10	7071-7074	and	_
31-11	7075-7079	glia	_
31-12	7080-7084	were	_
31-13	7085-7089	also	_
31-14	7090-7099	sequenced	_
31-15	7100-7102	to	_
31-16	7103-7110	enhance	_
31-17	7111-7121	resolution	_
31-18	7122-7123	.	_

Text=Initial processing of the raw 2 ×125 bp read pair FASTQ files was performed using the HiC-Pro analysis pipeline.
32-1	7124-7131	Initial	_
32-2	7132-7142	processing	_
32-3	7143-7145	of	_
32-4	7146-7149	the	_
32-5	7150-7153	raw	_
32-6	7154-7155	2	_
32-7	7156-7160	×125	_
32-8	7161-7163	bp	_
32-9	7164-7168	read	_
32-10	7169-7173	pair	_
32-11	7174-7179	FASTQ	_
32-12	7180-7185	files	_
32-13	7186-7189	was	_
32-14	7190-7199	performed	_
32-15	7200-7205	using	_
32-16	7206-7209	the	_
32-17	7210-7217	HiC-Pro	_
32-18	7218-7226	analysis	_
32-19	7227-7235	pipeline	_
32-20	7236-7237	.	_

Text=In brief, HiC-Pro performs four major tasks: aligning short reads, filtering for valid pairs, binning, and normalizing contact matrices.
33-1	7238-7240	In	_
33-2	7241-7246	brief	_
33-3	7247-7248	,	_
33-4	7249-7256	HiC-Pro	_
33-5	7257-7265	performs	_
33-6	7266-7270	four	_
33-7	7271-7276	major	_
33-8	7277-7282	tasks	_
33-9	7283-7284	:	_
33-10	7285-7293	aligning	_
33-11	7294-7299	short	_
33-12	7300-7305	reads	_
33-13	7306-7307	,	_
33-14	7308-7317	filtering	_
33-15	7318-7321	for	_
33-16	7322-7327	valid	_
33-17	7328-7333	pairs	_
33-18	7334-7335	,	_
33-19	7336-7343	binning	_
33-20	7344-7345	,	_
33-21	7346-7349	and	_
33-22	7350-7361	normalizing	_
33-23	7362-7369	contact	_
33-24	7370-7378	matrices	_
33-25	7379-7380	.	_

Text=HiCPro implements the truncation-based alignment strategy using Bowtie v2.2.3, mapping full reads end-to-end or the 5′ portion of reads preceding a GATCGATC ligation site that results from restriction enzyme digestion with MboI followed by end ligation.
34-1	7381-7387	HiCPro	_
34-2	7388-7398	implements	_
34-3	7399-7402	the	_
34-4	7403-7419	truncation-based	_
34-5	7420-7429	alignment	_
34-6	7430-7438	strategy	_
34-7	7439-7444	using	_
34-8	7445-7451	Bowtie	_
34-9	7452-7458	v2.2.3	_
34-10	7459-7460	,	_
34-11	7461-7468	mapping	_
34-12	7469-7473	full	_
34-13	7474-7479	reads	_
34-14	7480-7490	end-to-end	_
34-15	7491-7493	or	_
34-16	7494-7497	the	_
34-17	7498-7500	5′	_
34-18	7501-7508	portion	_
34-19	7509-7511	of	_
34-20	7512-7517	reads	_
34-21	7518-7527	preceding	_
34-22	7528-7529	a	_
34-23	7530-7538	GATCGATC	_
34-24	7539-7547	ligation	_
34-25	7548-7552	site	_
34-26	7553-7557	that	_
34-27	7558-7565	results	_
34-28	7566-7570	from	_
34-29	7571-7582	restriction	_
34-30	7583-7589	enzyme	_
34-31	7590-7599	digestion	_
34-32	7600-7604	with	_
34-33	7605-7609	MboI	_
34-34	7610-7618	followed	_
34-35	7619-7621	by	_
34-36	7622-7625	end	_
34-37	7626-7634	ligation	_
34-38	7635-7636	.	_

Text=Invalid interactions such as same-strand, dangling-end, self-cycle, and single-end pairs are not retained.
35-1	7637-7644	Invalid	_
35-2	7645-7657	interactions	_
35-3	7658-7662	such	_
35-4	7663-7665	as	_
35-5	7666-7677	same-strand	_
35-6	7678-7679	,	_
35-7	7680-7692	dangling-end	_
35-8	7693-7694	,	_
35-9	7695-7705	self-cycle	_
35-10	7706-7707	,	_
35-11	7708-7711	and	_
35-12	7712-7722	single-end	_
35-13	7723-7728	pairs	_
35-14	7729-7732	are	_
35-15	7733-7736	not	_
35-16	7737-7745	retained	_
35-17	7746-7747	.	_

Text=Binning was performed in 10kb, 40 kb and 100 kb non-overlapping, adjacent windows across the genome and resulting contact matrices were normalized using iterative correction and eigenvector decomposition (ICE) as previously described, using HiC-Pro ’ s default settings of 100 maximum iterations, filtering of the sparse bins (lowest 2%), and a relative result increment of 0.1 before declaring convergence (http: //nservant.github.io/HiC-Pro/MANUAL.html).
36-1	7748-7755	Binning	_
36-2	7756-7759	was	_
36-3	7760-7769	performed	_
36-4	7770-7772	in	_
36-5	7773-7777	10kb	_
36-6	7778-7779	,	_
36-7	7780-7782	40	_
36-8	7783-7785	kb	_
36-9	7786-7789	and	_
36-10	7790-7793	100	_
36-11	7794-7796	kb	_
36-12	7797-7812	non-overlapping	_
36-13	7813-7814	,	_
36-14	7815-7823	adjacent	_
36-15	7824-7831	windows	_
36-16	7832-7838	across	_
36-17	7839-7842	the	_
36-18	7843-7849	genome	_
36-19	7850-7853	and	_
36-20	7854-7863	resulting	_
36-21	7864-7871	contact	_
36-22	7872-7880	matrices	_
36-23	7881-7885	were	_
36-24	7886-7896	normalized	_
36-25	7897-7902	using	_
36-26	7903-7912	iterative	_
36-27	7913-7923	correction	_
36-28	7924-7927	and	_
36-29	7928-7939	eigenvector	_
36-30	7940-7953	decomposition	_
36-31	7954-7955	(	_
36-32	7956-7959	ICE	_
36-33	7960-7961	)	_
36-34	7962-7964	as	_
36-35	7965-7975	previously	_
36-36	7976-7985	described	_
36-37	7986-7987	,	_
36-38	7988-7993	using	_
36-39	7994-8001	HiC-Pro	_
36-40	8002-8003	’	_
36-41	8004-8005	s	_
36-42	8006-8013	default	_
36-43	8014-8022	settings	_
36-44	8023-8025	of	_
36-45	8026-8029	100	_
36-46	8030-8037	maximum	_
36-47	8038-8048	iterations	_
36-48	8049-8050	,	_
36-49	8051-8060	filtering	_
36-50	8061-8063	of	_
36-51	8064-8067	the	_
36-52	8068-8074	sparse	_
36-53	8075-8079	bins	_
36-54	8080-8081	(	_
36-55	8082-8088	lowest	_
36-56	8089-8090	2	_
36-57	8091-8092	%	_
36-58	8093-8094	)	_
36-59	8095-8096	,	_
36-60	8097-8100	and	_
36-61	8101-8102	a	_
36-62	8103-8111	relative	_
36-63	8112-8118	result	_
36-64	8119-8128	increment	_
36-65	8129-8131	of	_
36-66	8132-8135	0.1	_
36-67	8136-8142	before	_
36-68	8143-8152	declaring	_
36-69	8153-8164	convergence	_
36-70	8165-8166	(	_
36-71	8167-8171	http	_
36-72	8172-8173	:	_
36-73	8174-8214	//nservant.github.io/HiC-Pro/MANUAL.html	_
36-74	8215-8216	)	_
36-75	8217-8218	.	_

Text=Data are reported in browser-extensible-data-like (BED) format and visualized in the Washington University Epigenome Browser (http: //epigenomegateway.wustl.edu).
37-1	8219-8223	Data	_
37-2	8224-8227	are	_
37-3	8228-8236	reported	_
37-4	8237-8239	in	_
37-5	8240-8268	browser-extensible-data-like	_
37-6	8269-8270	(	_
37-7	8271-8274	BED	_
37-8	8275-8276	)	_
37-9	8277-8283	format	_
37-10	8284-8287	and	_
37-11	8288-8298	visualized	_
37-12	8299-8301	in	_
37-13	8302-8305	the	_
37-14	8306-8316	Washington	_
37-15	8317-8327	University	_
37-16	8328-8337	Epigenome	_
37-17	8338-8345	Browser	_
37-18	8346-8347	(	_
37-19	8348-8352	http	_
37-20	8353-8354	:	_
37-21	8355-8383	//epigenomegateway.wustl.edu	_
37-22	8384-8385	)	_
37-23	8386-8387	.	_

Text=Hierarchical clustering was performed on the ICE-corrected intrachromosomal contact matrices after the bins with the 1% most extreme interaction values were excluded as largely artifactual.
38-1	8388-8400	Hierarchical	_
38-2	8401-8411	clustering	_
38-3	8412-8415	was	_
38-4	8416-8425	performed	_
38-5	8426-8428	on	_
38-6	8429-8432	the	_
38-7	8433-8446	ICE-corrected	_
38-8	8447-8463	intrachromosomal	_
38-9	8464-8471	contact	_
38-10	8472-8480	matrices	_
38-11	8481-8486	after	_
38-12	8487-8490	the	_
38-13	8491-8495	bins	_
38-14	8496-8500	with	_
38-15	8501-8504	the	_
38-16	8505-8506	1	_
38-17	8507-8508	%	_
38-18	8509-8513	most	_
38-19	8514-8521	extreme	_
38-20	8522-8533	interaction	_
38-21	8534-8540	values	_
38-22	8541-8545	were	_
38-23	8546-8554	excluded	_
38-24	8555-8557	as	_
38-25	8558-8565	largely	_
38-26	8566-8577	artifactual	_
38-27	8578-8579	.	_

Text=Clustering was performed using Ward ’ s method on the 1, 5, 10, 25, 50, and 100% most variable remaining bins using (1-correlation) as a distance metric.
39-1	8580-8590	Clustering	_
39-2	8591-8594	was	_
39-3	8595-8604	performed	_
39-4	8605-8610	using	_
39-5	8611-8615	Ward	_
39-6	8616-8617	’	_
39-7	8618-8619	s	_
39-8	8620-8626	method	_
39-9	8627-8629	on	_
39-10	8630-8633	the	_
39-11	8634-8635	1	_
39-12	8636-8637	,	_
39-13	8638-8639	5	_
39-14	8640-8641	,	_
39-15	8642-8644	10	_
39-16	8645-8646	,	_
39-17	8647-8649	25	_
39-18	8650-8651	,	_
39-19	8652-8654	50	_
39-20	8655-8656	,	_
39-21	8657-8660	and	_
39-22	8661-8664	100	_
39-23	8665-8666	%	_
39-24	8667-8671	most	_
39-25	8672-8680	variable	_
39-26	8681-8690	remaining	_
39-27	8691-8695	bins	_
39-28	8696-8701	using	_
39-29	8702-8703	(	_
39-30	8704-8717	1-correlation	_
39-31	8718-8719	)	_
39-32	8720-8722	as	_
39-33	8723-8724	a	_
39-34	8725-8733	distance	_
39-35	8734-8740	metric	_
39-36	8741-8742	.	_

Text=The results using the 10% most variable interaction bins, shown here in a cluster dendrogram and a Pearson correlation matrix, are representative of these results.
40-1	8743-8746	The	_
40-2	8747-8754	results	_
40-3	8755-8760	using	_
40-4	8761-8764	the	_
40-5	8765-8767	10	_
40-6	8768-8769	%	_
40-7	8770-8774	most	_
40-8	8775-8783	variable	_
40-9	8784-8795	interaction	_
40-10	8796-8800	bins	_
40-11	8801-8802	,	_
40-12	8803-8808	shown	_
40-13	8809-8813	here	_
40-14	8814-8816	in	_
40-15	8817-8818	a	_
40-16	8819-8826	cluster	_
40-17	8827-8837	dendrogram	_
40-18	8838-8841	and	_
40-19	8842-8843	a	_
40-20	8844-8851	Pearson	_
40-21	8852-8863	correlation	_
40-22	8864-8870	matrix	_
40-23	8871-8872	,	_
40-24	8873-8876	are	_
40-25	8877-8891	representative	_
40-26	8892-8894	of	_
40-27	8895-8900	these	_
40-28	8901-8908	results	_
40-29	8909-8910	.	_

Text=Hi-C loop calls using Juicer Loop calling was performed using the software HiCCUPS.
41-1	8911-8915	Hi-C	_
41-2	8916-8920	loop	_
41-3	8921-8926	calls	_
41-4	8927-8932	using	_
41-5	8933-8939	Juicer	_
41-6	8940-8944	Loop	_
41-7	8945-8952	calling	_
41-8	8953-8956	was	_
41-9	8957-8966	performed	_
41-10	8967-8972	using	_
41-11	8973-8976	the	_
41-12	8977-8985	software	_
41-13	8986-8993	HiCCUPS	_
41-14	8994-8995	.	_

Text=To format data for HiCCUPS input, we remapped reads from Hi-C libraries using the Juicer pipeline.
42-1	8996-8998	To	_
42-2	8999-9005	format	_
42-3	9006-9010	data	_
42-4	9011-9014	for	_
42-5	9015-9022	HiCCUPS	_
42-6	9023-9028	input	_
42-7	9029-9030	,	_
42-8	9031-9033	we	_
42-9	9034-9042	remapped	_
42-10	9043-9048	reads	_
42-11	9049-9053	from	_
42-12	9054-9058	Hi-C	_
42-13	9059-9068	libraries	_
42-14	9069-9074	using	_
42-15	9075-9078	the	_
42-16	9079-9085	Juicer	_
42-17	9086-9094	pipeline	_
42-18	9095-9096	.	_

Text=Similar to HiC-Pro, the Juicer pipeline performs read alignment, filtering, binning, and matrix normalization.
43-1	9097-9104	Similar	_
43-2	9105-9107	to	_
43-3	9108-9115	HiC-Pro	_
43-4	9116-9117	,	_
43-5	9118-9121	the	_
43-6	9122-9128	Juicer	_
43-7	9129-9137	pipeline	_
43-8	9138-9146	performs	_
43-9	9147-9151	read	_
43-10	9152-9161	alignment	_
43-11	9162-9163	,	_
43-12	9164-9173	filtering	_
43-13	9174-9175	,	_
43-14	9176-9183	binning	_
43-15	9184-9185	,	_
43-16	9186-9189	and	_
43-17	9190-9196	matrix	_
43-18	9197-9210	normalization	_
43-19	9211-9212	.	_

Text=Samples were pooled for each cell type (S1 and 2 technical replicates from S2) to generate the maximum amount of coverage required for accurate loop calling.
44-1	9213-9220	Samples	_
44-2	9221-9225	were	_
44-3	9226-9232	pooled	_
44-4	9233-9236	for	_
44-5	9237-9241	each	_
44-6	9242-9246	cell	_
44-7	9247-9251	type	_
44-8	9252-9253	(	_
44-9	9254-9256	S1	_
44-10	9257-9260	and	_
44-11	9261-9262	2	_
44-12	9263-9272	technical	_
44-13	9273-9283	replicates	_
44-14	9284-9288	from	_
44-15	9289-9291	S2	_
44-16	9292-9293	)	_
44-17	9294-9296	to	_
44-18	9297-9305	generate	_
44-19	9306-9309	the	_
44-20	9310-9317	maximum	_
44-21	9318-9324	amount	_
44-22	9325-9327	of	_
44-23	9328-9336	coverage	_
44-24	9337-9345	required	_
44-25	9346-9349	for	_
44-26	9350-9358	accurate	_
44-27	9359-9363	loop	_
44-28	9364-9371	calling	_
44-29	9372-9373	.	_

Text=The resulting .hic matrix files (MAPQ> 0) were then used as input to HiCCUPS.
45-1	9374-9377	The	_
45-2	9378-9387	resulting	_
45-3	9388-9392	.hic	_
45-4	9393-9399	matrix	_
45-5	9400-9405	files	_
45-6	9406-9407	(	_
45-7	9408-9412	MAPQ	_
45-8	9413-9414	>	_
45-9	9415-9416	0	_
45-10	9417-9418	)	_
45-11	9419-9423	were	_
45-12	9424-9428	then	_
45-13	9429-9433	used	_
45-14	9434-9436	as	_
45-15	9437-9442	input	_
45-16	9443-9445	to	_
45-17	9446-9453	HiCCUPS	_
45-18	9454-9455	.	_

Text=The following parameters were set for HiCCUPS following the analysis in: FDR threshold (f) = 0.10, 0.10; peak width (p) = 4, 2; window width (i) = 7, 5; merge distance (d) = 20 kb, 20 kb.
46-1	9456-9459	The	_
46-2	9460-9469	following	_
46-3	9470-9480	parameters	_
46-4	9481-9485	were	_
46-5	9486-9489	set	_
46-6	9490-9493	for	_
46-7	9494-9501	HiCCUPS	_
46-8	9502-9511	following	_
46-9	9512-9515	the	_
46-10	9516-9524	analysis	_
46-11	9525-9527	in	_
46-12	9528-9529	:	_
46-13	9530-9533	FDR	_
46-14	9534-9543	threshold	_
46-15	9544-9545	(	_
46-16	9546-9547	f	_
46-17	9548-9549	)	_
46-18	9550-9551	=	_
46-19	9552-9556	0.10	_
46-20	9557-9558	,	_
46-21	9559-9563	0.10	_
46-22	9564-9565	;	_
46-23	9566-9570	peak	_
46-24	9571-9576	width	_
46-25	9577-9578	(	_
46-26	9579-9580	p	_
46-27	9581-9582	)	_
46-28	9583-9584	=	_
46-29	9585-9586	4	_
46-30	9587-9588	,	_
46-31	9589-9590	2	_
46-32	9591-9592	;	_
46-33	9593-9599	window	_
46-34	9600-9605	width	_
46-35	9606-9607	(	_
46-36	9608-9609	i	_
46-37	9610-9611	)	_
46-38	9612-9613	=	_
46-39	9614-9615	7	_
46-40	9616-9617	,	_
46-41	9618-9619	5	_
46-42	9620-9621	;	_
46-43	9622-9627	merge	_
46-44	9628-9636	distance	_
46-45	9637-9638	(	_
46-46	9639-9640	d	_
46-47	9641-9642	)	_
46-48	9643-9644	=	_
46-49	9645-9647	20	_
46-50	9648-9650	kb	_
46-51	9651-9652	,	_
46-52	9653-9655	20	_
46-53	9656-9658	kb	_
46-54	9659-9660	.	_

Text=Values for parameters correspond to calls made at 5kb and 10kb, respectively.
47-1	9661-9667	Values	_
47-2	9668-9671	for	_
47-3	9672-9682	parameters	_
47-4	9683-9693	correspond	_
47-5	9694-9696	to	_
47-6	9697-9702	calls	_
47-7	9703-9707	made	_
47-8	9708-9710	at	_
47-9	9711-9714	5kb	_
47-10	9715-9718	and	_
47-11	9719-9723	10kb	_
47-12	9724-9725	,	_
47-13	9726-9738	respectively	_
47-14	9739-9740	.	_

Text=Representative neuronal and non-neuronal loops are presented in fig.
48-1	9741-9755	Representative	_
48-2	9756-9764	neuronal	_
48-3	9765-9768	and	_
48-4	9769-9781	non-neuronal	_
48-5	9782-9787	loops	_
48-6	9788-9791	are	_
48-7	9792-9801	presented	_
48-8	9802-9804	in	_
48-9	9805-9808	fig	_
48-10	9809-9810	.	_

Text=S3.
49-1	9811-9813	S3	_
49-2	9814-9815	.	_

Text=As the number of loops called is dependent upon the number of Hi-C contacts in the matrix, we also generated matrices with equivalent total Hi-C contacts via subsampling.
50-1	9816-9818	As	_
50-2	9819-9822	the	_
50-3	9823-9829	number	_
50-4	9830-9832	of	_
50-5	9833-9838	loops	_
50-6	9839-9845	called	_
50-7	9846-9848	is	_
50-8	9849-9858	dependent	_
50-9	9859-9863	upon	_
50-10	9864-9867	the	_
50-11	9868-9874	number	_
50-12	9875-9877	of	_
50-13	9878-9882	Hi-C	_
50-14	9883-9891	contacts	_
50-15	9892-9894	in	_
50-16	9895-9898	the	_
50-17	9899-9905	matrix	_
50-18	9906-9907	,	_
50-19	9908-9910	we	_
50-20	9911-9915	also	_
50-21	9916-9925	generated	_
50-22	9926-9934	matrices	_
50-23	9935-9939	with	_
50-24	9940-9950	equivalent	_
50-25	9951-9956	total	_
50-26	9957-9961	Hi-C	_
50-27	9962-9970	contacts	_
50-28	9971-9974	via	_
50-29	9975-9986	subsampling	_
50-30	9987-9988	.	_

Text=hiPSC-derived Hi-C interaction matrices were randomly subsampled to 372,787,143 cis only contacts (the lowest number of cis contacts across all cell types) and HiCCUPS was rerun on the subsampled matrices.
51-1	9989-10002	hiPSC-derived	_
51-2	10003-10007	Hi-C	_
51-3	10008-10019	interaction	_
51-4	10020-10028	matrices	_
51-5	10029-10033	were	_
51-6	10034-10042	randomly	_
51-7	10043-10053	subsampled	_
51-8	10054-10056	to	_
51-9	10057-10068	372,787,143	_
51-10	10069-10072	cis	_
51-11	10073-10077	only	_
51-12	10078-10086	contacts	_
51-13	10087-10088	(	_
51-14	10089-10092	the	_
51-15	10093-10099	lowest	_
51-16	10100-10106	number	_
51-17	10107-10109	of	_
51-18	10110-10113	cis	_
51-19	10114-10122	contacts	_
51-20	10123-10129	across	_
51-21	10130-10133	all	_
51-22	10134-10138	cell	_
51-23	10139-10144	types	_
51-24	10145-10146	)	_
51-25	10147-10150	and	_
51-26	10151-10158	HiCCUPS	_
51-27	10159-10162	was	_
51-28	10163-10168	rerun	_
51-29	10169-10171	on	_
51-30	10172-10175	the	_
51-31	10176-10186	subsampled	_
51-32	10187-10195	matrices	_
51-33	10196-10197	.	_

Text=After loops were called for each cell type, we performed a reevaluation on this union set of loop loci.
52-1	10198-10203	After	_
52-2	10204-10209	loops	_
52-3	10210-10214	were	_
52-4	10215-10221	called	_
52-5	10222-10225	for	_
52-6	10226-10230	each	_
52-7	10231-10235	cell	_
52-8	10236-10240	type	_
52-9	10241-10242	,	_
52-10	10243-10245	we	_
52-11	10246-10255	performed	_
52-12	10256-10257	a	_
52-13	10258-10270	reevaluation	_
52-14	10271-10273	on	_
52-15	10274-10278	this	_
52-16	10279-10284	union	_
52-17	10285-10288	set	_
52-18	10289-10291	of	_
52-19	10292-10296	loop	_
52-20	10297-10301	loci	_
52-21	10302-10303	.	_

Text=HiCCUPS was rerun using the union set of loop loci as input to produce q-values for each loop in the union set for every cell type.
53-1	10304-10311	HiCCUPS	_
53-2	10312-10315	was	_
53-3	10316-10321	rerun	_
53-4	10322-10327	using	_
53-5	10328-10331	the	_
53-6	10332-10337	union	_
53-7	10338-10341	set	_
53-8	10342-10344	of	_
53-9	10345-10349	loop	_
53-10	10350-10354	loci	_
53-11	10355-10357	as	_
53-12	10358-10363	input	_
53-13	10364-10366	to	_
53-14	10367-10374	produce	_
53-15	10375-10383	q-values	_
53-16	10384-10387	for	_
53-17	10388-10392	each	_
53-18	10393-10397	loop	_
53-19	10398-10400	in	_
53-20	10401-10404	the	_
53-21	10405-10410	union	_
53-22	10411-10414	set	_
53-23	10415-10418	for	_
53-24	10419-10424	every	_
53-25	10425-10429	cell	_
53-26	10430-10434	type	_
53-27	10435-10436	.	_

Text=By default, HiCCUPS does not output a q-value for every pixel.
54-1	10437-10439	By	_
54-2	10440-10447	default	_
54-3	10448-10449	,	_
54-4	10450-10457	HiCCUPS	_
54-5	10458-10462	does	_
54-6	10463-10466	not	_
54-7	10467-10473	output	_
54-8	10474-10475	a	_
54-9	10476-10483	q-value	_
54-10	10484-10487	for	_
54-11	10488-10493	every	_
54-12	10494-10499	pixel	_
54-13	10500-10501	.	_

Text=Hence, this reevaluation produced q-values for pixels in cells that did not pass the significance threshold.
55-1	10502-10507	Hence	_
55-2	10508-10509	,	_
55-3	10510-10514	this	_
55-4	10515-10527	reevaluation	_
55-5	10528-10536	produced	_
55-6	10537-10545	q-values	_
55-7	10546-10549	for	_
55-8	10550-10556	pixels	_
55-9	10557-10559	in	_
55-10	10560-10565	cells	_
55-11	10566-10570	that	_
55-12	10571-10574	did	_
55-13	10575-10578	not	_
55-14	10579-10583	pass	_
55-15	10584-10587	the	_
55-16	10588-10600	significance	_
55-17	10601-10610	threshold	_
55-18	10611-10612	.	_

Text=We then defined any pixel from the union set with a q-value <0.10 with respect to the donut neighborhood surrounding the pixel to be a loop and defined the loop to be shared with any cell types having a q-value <0.10 for the same pixel.
56-1	10613-10615	We	_
56-2	10616-10620	then	_
56-3	10621-10628	defined	_
56-4	10629-10632	any	_
56-5	10633-10638	pixel	_
56-6	10639-10643	from	_
56-7	10644-10647	the	_
56-8	10648-10653	union	_
56-9	10654-10657	set	_
56-10	10658-10662	with	_
56-11	10663-10664	a	_
56-12	10665-10672	q-value	_
56-13	10673-10674	<	_
56-14	10675-10679	0.10	_
56-15	10680-10684	with	_
56-16	10685-10692	respect	_
56-17	10693-10695	to	_
56-18	10696-10699	the	_
56-19	10700-10705	donut	_
56-20	10706-10718	neighborhood	_
56-21	10719-10730	surrounding	_
56-22	10731-10734	the	_
56-23	10735-10740	pixel	_
56-24	10741-10743	to	_
56-25	10744-10746	be	_
56-26	10747-10748	a	_
56-27	10749-10753	loop	_
56-28	10754-10757	and	_
56-29	10758-10765	defined	_
56-30	10766-10769	the	_
56-31	10770-10774	loop	_
56-32	10775-10777	to	_
56-33	10778-10780	be	_
56-34	10781-10787	shared	_
56-35	10788-10792	with	_
56-36	10793-10796	any	_
56-37	10797-10801	cell	_
56-38	10802-10807	types	_
56-39	10808-10814	having	_
56-40	10815-10816	a	_
56-41	10817-10824	q-value	_
56-42	10825-10826	<	_
56-43	10827-10831	0.10	_
56-44	10832-10835	for	_
56-45	10836-10839	the	_
56-46	10840-10844	same	_
56-47	10845-10850	pixel	_
56-48	10851-10852	.	_

Text=These loop calls were used for comparing loop calls between cell types.
57-1	10853-10858	These	_
57-2	10859-10863	loop	_
57-3	10864-10869	calls	_
57-4	10870-10874	were	_
57-5	10875-10879	used	_
57-6	10880-10883	for	_
57-7	10884-10893	comparing	_
57-8	10894-10898	loop	_
57-9	10899-10904	calls	_
57-10	10905-10912	between	_
57-11	10913-10917	cell	_
57-12	10918-10923	types	_
57-13	10924-10925	.	_

Text=Loops were also called and subsampled as above for the GM12878 cell line using the processed data from found here: www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE63525.
58-1	10926-10931	Loops	_
58-2	10932-10936	were	_
58-3	10937-10941	also	_
58-4	10942-10948	called	_
58-5	10949-10952	and	_
58-6	10953-10963	subsampled	_
58-7	10964-10966	as	_
58-8	10967-10972	above	_
58-9	10973-10976	for	_
58-10	10977-10980	the	_
58-11	10981-10988	GM12878	_
58-12	10989-10993	cell	_
58-13	10994-10998	line	_
58-14	10999-11004	using	_
58-15	11005-11008	the	_
58-16	11009-11018	processed	_
58-17	11019-11023	data	_
58-18	11024-11028	from	_
58-19	11029-11034	found	_
58-20	11035-11039	here	_
58-21	11040-11041	:	_
58-22	11042-11080	www.ncbi.nlm.nih.gov/geo/query/acc.cgi	_
58-23	11081-11082	?	_
58-24	11083-11095	acc=GSE63525	_
58-25	11096-11097	.	_

Text=Loop calls were overlapped with compartment calls (supplementary materials, materials and methods), such that AA, BB, and AB refer to loops with both anchors in A, both anchors in B, and one anchor in A and other anchor in B, respectively.
59-1	11098-11102	Loop	_
59-2	11103-11108	calls	_
59-3	11109-11113	were	_
59-4	11114-11124	overlapped	_
59-5	11125-11129	with	_
59-6	11130-11141	compartment	_
59-7	11142-11147	calls	_
59-8	11148-11149	(	_
59-9	11150-11163	supplementary	_
59-10	11164-11173	materials	_
59-11	11174-11175	,	_
59-12	11176-11185	materials	_
59-13	11186-11189	and	_
59-14	11190-11197	methods	_
59-15	11198-11199	)	_
59-16	11200-11201	,	_
59-17	11202-11206	such	_
59-18	11207-11211	that	_
59-19	11212-11214	AA	_
59-20	11215-11216	,	_
59-21	11217-11219	BB	_
59-22	11220-11221	,	_
59-23	11222-11225	and	_
59-24	11226-11228	AB	_
59-25	11229-11234	refer	_
59-26	11235-11237	to	_
59-27	11238-11243	loops	_
59-28	11244-11248	with	_
59-29	11249-11253	both	_
59-30	11254-11261	anchors	_
59-31	11262-11264	in	_
59-32	11265-11266	A	_
59-33	11267-11268	,	_
59-34	11269-11273	both	_
59-35	11274-11281	anchors	_
59-36	11282-11284	in	_
59-37	11285-11286	B	_
59-38	11287-11288	,	_
59-39	11289-11292	and	_
59-40	11293-11296	one	_
59-41	11297-11303	anchor	_
59-42	11304-11306	in	_
59-43	11307-11308	A	_
59-44	11309-11312	and	_
59-45	11313-11318	other	_
59-46	11319-11325	anchor	_
59-47	11326-11328	in	_
59-48	11329-11330	B	_
59-49	11331-11332	,	_
59-50	11333-11345	respectively	_
59-51	11346-11347	.	_

Text=Loops in chromosomes 4, 18, 19, and X were removed from this compartment analysis since the first principle component most likely corresponded to p versus q arm distinctions and not A versus B compartments.
60-1	11348-11353	Loops	_
60-2	11354-11356	in	_
60-3	11357-11368	chromosomes	_
60-4	11369-11370	4	_
60-5	11371-11372	,	_
60-6	11373-11375	18	_
60-7	11376-11377	,	_
60-8	11378-11380	19	_
60-9	11381-11382	,	_
60-10	11383-11386	and	_
60-11	11387-11388	X	_
60-12	11389-11393	were	_
60-13	11394-11401	removed	_
60-14	11402-11406	from	_
60-15	11407-11411	this	_
60-16	11412-11423	compartment	_
60-17	11424-11432	analysis	_
60-18	11433-11438	since	_
60-19	11439-11442	the	_
60-20	11443-11448	first	_
60-21	11449-11458	principle	_
60-22	11459-11468	component	_
60-23	11469-11473	most	_
60-24	11474-11480	likely	_
60-25	11481-11493	corresponded	_
60-26	11494-11496	to	_
60-27	11497-11498	p	_
60-28	11499-11505	versus	_
60-29	11506-11507	q	_
60-30	11508-11511	arm	_
60-31	11512-11524	distinctions	_
60-32	11525-11528	and	_
60-33	11529-11532	not	_
60-34	11533-11534	A	_
60-35	11535-11541	versus	_
60-36	11542-11543	B	_
60-37	11544-11556	compartments	_
60-38	11557-11558	.	_

Text=Hi-C interactions at risk loci To approach 3DG conformation in context of the disease-relevant sequences, we adapted the binomial statistics based mapping strategy previously described by Won et al ..
61-1	11559-11563	Hi-C	_
61-2	11564-11576	interactions	_
61-3	11577-11579	at	_
61-4	11580-11584	risk	_
61-5	11585-11589	loci	_
61-6	11590-11592	To	_
61-7	11593-11601	approach	_
61-8	11602-11605	3DG	_
61-9	11606-11618	conformation	_
61-10	11619-11621	in	_
61-11	11622-11629	context	_
61-12	11630-11632	of	_
61-13	11633-11636	the	_
61-14	11637-11653	disease-relevant	_
61-15	11654-11663	sequences	_
61-16	11664-11665	,	_
61-17	11666-11668	we	_
61-18	11669-11676	adapted	_
61-19	11677-11680	the	_
61-20	11681-11689	binomial	_
61-21	11690-11700	statistics	_
61-22	11701-11706	based	_
61-23	11707-11714	mapping	_
61-24	11715-11723	strategy	_
61-25	11724-11734	previously	_
61-26	11735-11744	described	_
61-27	11745-11747	by	_
61-28	11748-11751	Won	_
61-29	11752-11754	et	_
61-30	11755-11757	al	_
61-31	11758-11760	..	_

Text=The set of schizophrenia risk loci used in this study included the original (PGC2, Psychiatric Genomics Consortium) risk sequences, or 108 physically distinct association loci defined by 128 index SNPs (corrected P 10−8) and an additional 37 loci from the CLOZUK (a series of UK cases registered for clozapine treatment with a clinical diagnosis of schizophrenia) study for a total of 145 loci defined by 179 independent genome-wide significant SNPs (corrected P <5 × 10–8), determined by GWAS in 40,675 cases and 64,643 controls.
62-1	11761-11764	The	_
62-2	11765-11768	set	_
62-3	11769-11771	of	_
62-4	11772-11785	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
62-5	11786-11790	risk	_
62-6	11791-11795	loci	_
62-7	11796-11800	used	_
62-8	11801-11803	in	_
62-9	11804-11808	this	_
62-10	11809-11814	study	_
62-11	11815-11823	included	_
62-12	11824-11827	the	_
62-13	11828-11836	original	_
62-14	11837-11838	(	_
62-15	11839-11843	PGC2	_
62-16	11844-11845	,	_
62-17	11846-11857	Psychiatric	_
62-18	11858-11866	Genomics	_
62-19	11867-11877	Consortium	_
62-20	11878-11879	)	_
62-21	11880-11884	risk	_
62-22	11885-11894	sequences	_
62-23	11895-11896	,	_
62-24	11897-11899	or	_
62-25	11900-11903	108	_
62-26	11904-11914	physically	_
62-27	11915-11923	distinct	_
62-28	11924-11935	association	_
62-29	11936-11940	loci	_
62-30	11941-11948	defined	_
62-31	11949-11951	by	_
62-32	11952-11955	128	_
62-33	11956-11961	index	_
62-34	11962-11966	SNPs	_
62-35	11967-11968	(	_
62-36	11969-11978	corrected	_
62-37	11979-11980	P	_
62-38	11981-11985	10−8	_
62-39	11986-11987	)	_
62-40	11988-11991	and	_
62-41	11992-11994	an	_
62-42	11995-12005	additional	_
62-43	12006-12008	37	_
62-44	12009-12013	loci	_
62-45	12014-12018	from	_
62-46	12019-12022	the	_
62-47	12023-12029	CLOZUK	_
62-48	12030-12031	(	_
62-49	12032-12033	a	_
62-50	12034-12040	series	_
62-51	12041-12043	of	_
62-52	12044-12046	UK	_
62-53	12047-12052	cases	_
62-54	12053-12063	registered	_
62-55	12064-12067	for	_
62-56	12068-12077	clozapine	_
62-57	12078-12087	treatment	_
62-58	12088-12092	with	_
62-59	12093-12094	a	_
62-60	12095-12103	clinical	_
62-61	12104-12113	diagnosis	_
62-62	12114-12116	of	_
62-63	12117-12130	schizophrenia	_
62-64	12131-12132	)	_
62-65	12133-12138	study	_
62-66	12139-12142	for	_
62-67	12143-12144	a	_
62-68	12145-12150	total	_
62-69	12151-12153	of	_
62-70	12154-12157	145	_
62-71	12158-12162	loci	_
62-72	12163-12170	defined	_
62-73	12171-12173	by	_
62-74	12174-12177	179	_
62-75	12178-12189	independent	_
62-76	12190-12201	genome-wide	_
62-77	12202-12213	significant	_
62-78	12214-12218	SNPs	_
62-79	12219-12220	(	_
62-80	12221-12230	corrected	_
62-81	12231-12232	P	_
62-82	12233-12234	<	_
62-83	12235-12236	5	_
62-84	12237-12238	×	_
62-85	12239-12243	10–8	_
62-86	12244-12245	)	_
62-87	12246-12247	,	_
62-88	12248-12258	determined	_
62-89	12259-12261	by	_
62-90	12262-12266	GWAS	_
62-91	12267-12269	in	_
62-92	12270-12276	40,675	_
62-93	12277-12282	cases	_
62-94	12283-12286	and	_
62-95	12287-12293	64,643	_
62-96	12294-12302	controls	_
62-97	12303-12304	.	_

Text=A risk locus is defined as a collection of (SNPs) existing in linkage dis-equilibrium, ranging from 1bp to 8.9Mb (average 256.2 kb) in length and in total equivalent to approximately 0.012% of human genomic sequence.
63-1	12305-12306	A	_
63-2	12307-12311	risk	_
63-3	12312-12317	locus	_
63-4	12318-12320	is	_
63-5	12321-12328	defined	_
63-6	12329-12331	as	_
63-7	12332-12333	a	_
63-8	12334-12344	collection	_
63-9	12345-12347	of	_
63-10	12348-12349	(	_
63-11	12350-12354	SNPs	_
63-12	12355-12356	)	_
63-13	12357-12365	existing	_
63-14	12366-12368	in	_
63-15	12369-12376	linkage	_
63-16	12377-12392	dis-equilibrium	_
63-17	12393-12394	,	_
63-18	12395-12402	ranging	_
63-19	12403-12407	from	_
63-20	12408-12411	1bp	_
63-21	12412-12414	to	_
63-22	12415-12420	8.9Mb	_
63-23	12421-12422	(	_
63-24	12423-12430	average	_
63-25	12431-12436	256.2	_
63-26	12437-12439	kb	_
63-27	12440-12441	)	_
63-28	12442-12444	in	_
63-29	12445-12451	length	_
63-30	12452-12455	and	_
63-31	12456-12458	in	_
63-32	12459-12464	total	_
63-33	12465-12475	equivalent	_
63-34	12476-12478	to	_
63-35	12479-12492	approximately	_
63-36	12493-12498	0.012	_
63-37	12499-12500	%	_
63-38	12501-12503	of	_
63-39	12504-12509	human	_
63-40	12510-12517	genomic	_
63-41	12518-12526	sequence	_
63-42	12527-12528	.	_

Text=To identify significantly enriched interactions involving a bin of interest with another bin, our principal approach was to first estimate the expected interaction counts for each interaction distance by calculating the mean of all intrachromosomal bin-bin interactions of the same separation distance throughout the raw intrachromosomal contact matrix.
64-1	12529-12531	To	_
64-2	12532-12540	identify	_
64-3	12541-12554	significantly	_
64-4	12555-12563	enriched	_
64-5	12564-12576	interactions	_
64-6	12577-12586	involving	_
64-7	12587-12588	a	_
64-8	12589-12592	bin	_
64-9	12593-12595	of	_
64-10	12596-12604	interest	_
64-11	12605-12609	with	_
64-12	12610-12617	another	_
64-13	12618-12621	bin	_
64-14	12622-12623	,	_
64-15	12624-12627	our	_
64-16	12628-12637	principal	_
64-17	12638-12646	approach	_
64-18	12647-12650	was	_
64-19	12651-12653	to	_
64-20	12654-12659	first	_
64-21	12660-12668	estimate	_
64-22	12669-12672	the	_
64-23	12673-12681	expected	_
64-24	12682-12693	interaction	_
64-25	12694-12700	counts	_
64-26	12701-12704	for	_
64-27	12705-12709	each	_
64-28	12710-12721	interaction	_
64-29	12722-12730	distance	_
64-30	12731-12733	by	_
64-31	12734-12745	calculating	_
64-32	12746-12749	the	_
64-33	12750-12754	mean	_
64-34	12755-12757	of	_
64-35	12758-12761	all	_
64-36	12762-12778	intrachromosomal	_
64-37	12779-12786	bin-bin	_
64-38	12787-12799	interactions	_
64-39	12800-12802	of	_
64-40	12803-12806	the	_
64-41	12807-12811	same	_
64-42	12812-12822	separation	_
64-43	12823-12831	distance	_
64-44	12832-12842	throughout	_
64-45	12843-12846	the	_
64-46	12847-12850	raw	_
64-47	12851-12867	intrachromosomal	_
64-48	12868-12875	contact	_
64-49	12876-12882	matrix	_
64-50	12883-12884	.	_

Text=We used the R package, HiTC, to facilitate manipulation of our HiC-Pro-produced raw contact matrices and estimation of the expected counts at various interaction distances.
65-1	12885-12887	We	_
65-2	12888-12892	used	_
65-3	12893-12896	the	_
65-4	12897-12898	R	_
65-5	12899-12906	package	_
65-6	12907-12908	,	_
65-7	12909-12913	HiTC	_
65-8	12914-12915	,	_
65-9	12916-12918	to	_
65-10	12919-12929	facilitate	_
65-11	12930-12942	manipulation	_
65-12	12943-12945	of	_
65-13	12946-12949	our	_
65-14	12950-12966	HiC-Pro-produced	_
65-15	12967-12970	raw	_
65-16	12971-12978	contact	_
65-17	12979-12987	matrices	_
65-18	12988-12991	and	_
65-19	12992-13002	estimation	_
65-20	13003-13005	of	_
65-21	13006-13009	the	_
65-22	13010-13018	expected	_
65-23	13019-13025	counts	_
65-24	13026-13028	at	_
65-25	13029-13036	various	_
65-26	13037-13048	interaction	_
65-27	13049-13058	distances	_
65-28	13059-13060	.	_

Text=The probability of observing an interaction between a bin-of-interest and another bin was then defined as the expected interaction between those two bins divided by the sum of all expected interactions between the bin-of-interest and all other intrachromosomal bins.
66-1	13061-13064	The	_
66-2	13065-13076	probability	_
66-3	13077-13079	of	_
66-4	13080-13089	observing	_
66-5	13090-13092	an	_
66-6	13093-13104	interaction	_
66-7	13105-13112	between	_
66-8	13113-13114	a	_
66-9	13115-13130	bin-of-interest	_
66-10	13131-13134	and	_
66-11	13135-13142	another	_
66-12	13143-13146	bin	_
66-13	13147-13150	was	_
66-14	13151-13155	then	_
66-15	13156-13163	defined	_
66-16	13164-13166	as	_
66-17	13167-13170	the	_
66-18	13171-13179	expected	_
66-19	13180-13191	interaction	_
66-20	13192-13199	between	_
66-21	13200-13205	those	_
66-22	13206-13209	two	_
66-23	13210-13214	bins	_
66-24	13215-13222	divided	_
66-25	13223-13225	by	_
66-26	13226-13229	the	_
66-27	13230-13233	sum	_
66-28	13234-13236	of	_
66-29	13237-13240	all	_
66-30	13241-13249	expected	_
66-31	13250-13262	interactions	_
66-32	13263-13270	between	_
66-33	13271-13274	the	_
66-34	13275-13290	bin-of-interest	_
66-35	13291-13294	and	_
66-36	13295-13298	all	_
66-37	13299-13304	other	_
66-38	13305-13321	intrachromosomal	_
66-39	13322-13326	bins	_
66-40	13327-13328	.	_

Text=A P value was then calculated as binomial probability of observing the number of interaction counts or more between the bin-of-interest and some other bin where the number of successes was defined as the observed interaction count, the number of tries as the total number of observed interactions between the bin-of-interest and all other intrachromosomal bins, and the success probability as the probability of observing the bin-bin interaction estimated from the expected mean interaction counts.
67-1	13329-13330	A	_
67-2	13331-13332	P	_
67-3	13333-13338	value	_
67-4	13339-13342	was	_
67-5	13343-13347	then	_
67-6	13348-13358	calculated	_
67-7	13359-13361	as	_
67-8	13362-13370	binomial	_
67-9	13371-13382	probability	_
67-10	13383-13385	of	_
67-11	13386-13395	observing	_
67-12	13396-13399	the	_
67-13	13400-13406	number	_
67-14	13407-13409	of	_
67-15	13410-13421	interaction	_
67-16	13422-13428	counts	_
67-17	13429-13431	or	_
67-18	13432-13436	more	_
67-19	13437-13444	between	_
67-20	13445-13448	the	_
67-21	13449-13464	bin-of-interest	_
67-22	13465-13468	and	_
67-23	13469-13473	some	_
67-24	13474-13479	other	_
67-25	13480-13483	bin	_
67-26	13484-13489	where	_
67-27	13490-13493	the	_
67-28	13494-13500	number	_
67-29	13501-13503	of	_
67-30	13504-13513	successes	_
67-31	13514-13517	was	_
67-32	13518-13525	defined	_
67-33	13526-13528	as	_
67-34	13529-13532	the	_
67-35	13533-13541	observed	_
67-36	13542-13553	interaction	_
67-37	13554-13559	count	_
67-38	13560-13561	,	_
67-39	13562-13565	the	_
67-40	13566-13572	number	_
67-41	13573-13575	of	_
67-42	13576-13581	tries	_
67-43	13582-13584	as	_
67-44	13585-13588	the	_
67-45	13589-13594	total	_
67-46	13595-13601	number	_
67-47	13602-13604	of	_
67-48	13605-13613	observed	_
67-49	13614-13626	interactions	_
67-50	13627-13634	between	_
67-51	13635-13638	the	_
67-52	13639-13654	bin-of-interest	_
67-53	13655-13658	and	_
67-54	13659-13662	all	_
67-55	13663-13668	other	_
67-56	13669-13685	intrachromosomal	_
67-57	13686-13690	bins	_
67-58	13691-13692	,	_
67-59	13693-13696	and	_
67-60	13697-13700	the	_
67-61	13701-13708	success	_
67-62	13709-13720	probability	_
67-63	13721-13723	as	_
67-64	13724-13727	the	_
67-65	13728-13739	probability	_
67-66	13740-13742	of	_
67-67	13743-13752	observing	_
67-68	13753-13756	the	_
67-69	13757-13764	bin-bin	_
67-70	13765-13776	interaction	_
67-71	13777-13786	estimated	_
67-72	13787-13791	from	_
67-73	13792-13795	the	_
67-74	13796-13804	expected	_
67-75	13805-13809	mean	_
67-76	13810-13821	interaction	_
67-77	13822-13828	counts	_
67-78	13829-13830	.	_

Text=The Benjamini-Hochberg method was used to control false discovery rate (FDR) for P values determined for all interactions with a bin-of-interest (includes all bins 1Mb up and downstream in our tests).
68-1	13831-13834	The	_
68-2	13835-13853	Benjamini-Hochberg	_
68-3	13854-13860	method	_
68-4	13861-13864	was	_
68-5	13865-13869	used	_
68-6	13870-13872	to	_
68-7	13873-13880	control	_
68-8	13881-13886	false	_
68-9	13887-13896	discovery	_
68-10	13897-13901	rate	_
68-11	13902-13903	(	_
68-12	13904-13907	FDR	_
68-13	13908-13909	)	_
68-14	13910-13913	for	_
68-15	13914-13915	P	_
68-16	13916-13922	values	_
68-17	13923-13933	determined	_
68-18	13934-13937	for	_
68-19	13938-13941	all	_
68-20	13942-13954	interactions	_
68-21	13955-13959	with	_
68-22	13960-13961	a	_
68-23	13962-13977	bin-of-interest	_
68-24	13978-13979	(	_
68-25	13980-13988	includes	_
68-26	13989-13992	all	_
68-27	13993-13997	bins	_
68-28	13998-14001	1Mb	_
68-29	14002-14004	up	_
68-30	14005-14008	and	_
68-31	14009-14019	downstream	_
68-32	14020-14022	in	_
68-33	14023-14026	our	_
68-34	14027-14032	tests	_
68-35	14033-14034	)	_
68-36	14035-14036	.	_

Text=Generation of stable selected dCas9-VP64/VPR and Cas9 NPCs All CRISPR-based epigenomic editing assays were performed on antibiotic-selected dCas9-VP64 (VP64 as the tetrameric VP16 activator domain) and dCas9-VPR (VPR as the tripartite activator, VP64-p65-Rta) NPCs derived as described in.
69-1	14037-14047	Generation	_
69-2	14048-14050	of	_
69-3	14051-14057	stable	_
69-4	14058-14066	selected	_
69-5	14067-14081	dCas9-VP64/VPR	_
69-6	14082-14085	and	_
69-7	14086-14090	Cas9	_
69-8	14091-14095	NPCs	_
69-9	14096-14099	All	_
69-10	14100-14112	CRISPR-based	_
69-11	14113-14123	epigenomic	_
69-12	14124-14131	editing	_
69-13	14132-14138	assays	_
69-14	14139-14143	were	_
69-15	14144-14153	performed	_
69-16	14154-14156	on	_
69-17	14157-14176	antibiotic-selected	_
69-18	14177-14187	dCas9-VP64	_
69-19	14188-14189	(	_
69-20	14190-14194	VP64	_
69-21	14195-14197	as	_
69-22	14198-14201	the	_
69-23	14202-14212	tetrameric	_
69-24	14213-14217	VP16	_
69-25	14218-14227	activator	_
69-26	14228-14234	domain	_
69-27	14235-14236	)	_
69-28	14237-14240	and	_
69-29	14241-14250	dCas9-VPR	_
69-30	14251-14252	(	_
69-31	14253-14256	VPR	_
69-32	14257-14259	as	_
69-33	14260-14263	the	_
69-34	14264-14274	tripartite	_
69-35	14275-14284	activator	_
69-36	14285-14286	,	_
69-37	14287-14299	VP64-p65-Rta	_
69-38	14300-14301	)	_
69-39	14302-14306	NPCs	_
69-40	14307-14314	derived	_
69-41	14315-14317	as	_
69-42	14318-14327	described	_
69-43	14328-14330	in	_
69-44	14331-14332	.	_

Text=For generation of Cas9 stable, selected NPCs, we used a plasmid of lentiCRISPR v2 gifted by Feng Zhang (Addgene plasmid #52961).
70-1	14333-14336	For	_
70-2	14337-14347	generation	_
70-3	14348-14350	of	_
70-4	14351-14355	Cas9	_
70-5	14356-14362	stable	_
70-6	14363-14364	,	_
70-7	14365-14373	selected	_
70-8	14374-14378	NPCs	_
70-9	14379-14380	,	_
70-10	14381-14383	we	_
70-11	14384-14388	used	_
70-12	14389-14390	a	_
70-13	14391-14398	plasmid	_
70-14	14399-14401	of	_
70-15	14402-14413	lentiCRISPR	_
70-16	14414-14416	v2	_
70-17	14417-14423	gifted	_
70-18	14424-14426	by	_
70-19	14427-14431	Feng	_
70-20	14432-14437	Zhang	_
70-21	14438-14439	(	_
70-22	14440-14447	Addgene	_
70-23	14448-14455	plasmid	_
70-24	14456-14457	#	_
70-25	14458-14463	52961	_
70-26	14464-14465	)	_
70-27	14466-14467	.	_

Text=DNA sequencing with a U6 primer confirmed the identity.
71-1	14468-14471	DNA	_
71-2	14472-14482	sequencing	_
71-3	14483-14487	with	_
71-4	14488-14489	a	_
71-5	14490-14492	U6	_
71-6	14493-14499	primer	_
71-7	14500-14509	confirmed	_
71-8	14510-14513	the	_
71-9	14514-14522	identity	_
71-10	14523-14524	.	_

Text=Lentiviral production and titration were performed as described previously.
72-1	14525-14535	Lentiviral	_
72-2	14536-14546	production	_
72-3	14547-14550	and	_
72-4	14551-14560	titration	_
72-5	14561-14565	were	_
72-6	14566-14575	performed	_
72-7	14576-14578	as	_
72-8	14579-14588	described	_
72-9	14589-14599	previously	_
72-10	14600-14601	.	_

Text=Control S1 and S2 NPCs were spinfected with lentiCRISPR v2 virus as described.
73-1	14602-14609	Control	_
73-2	14610-14612	S1	_
73-3	14613-14616	and	_
73-4	14617-14619	S2	_
73-5	14620-14624	NPCs	_
73-6	14625-14629	were	_
73-7	14630-14640	spinfected	_
73-8	14641-14645	with	_
73-9	14646-14657	lentiCRISPR	_
73-10	14658-14660	v2	_
73-11	14661-14666	virus	_
73-12	14667-14669	as	_
73-13	14670-14679	described	_
73-14	14680-14681	.	_

Text=48 hours post-transduction, cells were selected by exposure to puromycin at 0.3 μg/mL.
74-1	14682-14684	48	_
74-2	14685-14690	hours	_
74-3	14691-14708	post-transduction	_
74-4	14709-14710	,	_
74-5	14711-14716	cells	_
74-6	14717-14721	were	_
74-7	14722-14730	selected	_
74-8	14731-14733	by	_
74-9	14734-14742	exposure	_
74-10	14743-14745	to	_
74-11	14746-14755	puromycin	_
74-12	14756-14758	at	_
74-13	14759-14762	0.3	_
74-14	14763-14768	μg/mL	_
74-15	14769-14770	.	_

Text=Without transduction, all control cells died within around 5 days after the antibiotic addition.
75-1	14771-14778	Without	_
75-2	14779-14791	transduction	_
75-3	14792-14793	,	_
75-4	14794-14797	all	_
75-5	14798-14805	control	_
75-6	14806-14811	cells	_
75-7	14812-14816	died	_
75-8	14817-14823	within	_
75-9	14824-14830	around	_
75-10	14831-14832	5	_
75-11	14833-14837	days	_
75-12	14838-14843	after	_
75-13	14844-14847	the	_
75-14	14848-14858	antibiotic	_
75-15	14859-14867	addition	_
75-16	14868-14869	.	_

Text=The puromycin-selected NPCs were subject to Western blot analysis of Cas9 expression.
76-1	14870-14873	The	_
76-2	14874-14892	puromycin-selected	_
76-3	14893-14897	NPCs	_
76-4	14898-14902	were	_
76-5	14903-14910	subject	_
76-6	14911-14913	to	_
76-7	14914-14921	Western	_
76-8	14922-14926	blot	_
76-9	14927-14935	analysis	_
76-10	14936-14938	of	_
76-11	14939-14943	Cas9	_
76-12	14944-14954	expression	_
76-13	14955-14956	.	_

Text=30 μg of proteins were electrophoresed in NuPAGE 4–12% Bis-Tris Protein Gels (NP0323PK2, Life Technologies) in 1× MES running buffer, 200 V constant, 35 min.
77-1	14957-14959	30	_
77-2	14960-14962	μg	_
77-3	14963-14965	of	_
77-4	14966-14974	proteins	_
77-5	14975-14979	were	_
77-6	14980-14995	electrophoresed	_
77-7	14996-14998	in	_
77-8	14999-15005	NuPAGE	_
77-9	15006-15010	4–12	_
77-10	15011-15012	%	_
77-11	15013-15021	Bis-Tris	_
77-12	15022-15029	Protein	_
77-13	15030-15034	Gels	_
77-14	15035-15036	(	_
77-15	15037-15046	NP0323PK2	_
77-16	15047-15048	,	_
77-17	15049-15053	Life	_
77-18	15054-15066	Technologies	_
77-19	15067-15068	)	_
77-20	15069-15071	in	_
77-21	15072-15074	1×	_
77-22	15075-15078	MES	_
77-23	15079-15086	running	_
77-24	15087-15093	buffer	_
77-25	15094-15095	,	_
77-26	15096-15099	200	_
77-27	15100-15101	V	_
77-28	15102-15110	constant	_
77-29	15111-15112	,	_
77-30	15113-15115	35	_
77-31	15116-15119	min	_
77-32	15120-15121	.	_

Text=Proteins were transferred onto nitrocellulose membrane (IB23002, Life Technologies) on the iBlot® 2 Dry Blotting System (program P3, 7:00 min).
78-1	15122-15130	Proteins	_
78-2	15131-15135	were	_
78-3	15136-15147	transferred	_
78-4	15148-15152	onto	_
78-5	15153-15167	nitrocellulose	_
78-6	15168-15176	membrane	_
78-7	15177-15178	(	_
78-8	15179-15186	IB23002	_
78-9	15187-15188	,	_
78-10	15189-15193	Life	_
78-11	15194-15206	Technologies	_
78-12	15207-15208	)	_
78-13	15209-15211	on	_
78-14	15212-15215	the	_
78-15	15216-15222	iBlot®	_
78-16	15223-15224	2	_
78-17	15225-15228	Dry	_
78-18	15229-15237	Blotting	_
78-19	15238-15244	System	_
78-20	15245-15246	(	_
78-21	15247-15254	program	_
78-22	15255-15257	P3	_
78-23	15258-15259	,	_
78-24	15260-15264	7:00	_
78-25	15265-15268	min	_
78-26	15269-15270	)	_
78-27	15271-15272	.	_

Text=The membranes were incubated with primary antibodies against Cas9 (1:250, monoclonal, clone 7A9, Millipore) and β-Actin (1:10,000, mouse, 1406030, Ambion) overnight at 4°C.
79-1	15273-15276	The	_
79-2	15277-15286	membranes	_
79-3	15287-15291	were	_
79-4	15292-15301	incubated	_
79-5	15302-15306	with	_
79-6	15307-15314	primary	_
79-7	15315-15325	antibodies	_
79-8	15326-15333	against	_
79-9	15334-15338	Cas9	_
79-10	15339-15340	(	_
79-11	15341-15346	1:250	_
79-12	15347-15348	,	_
79-13	15349-15359	monoclonal	_
79-14	15360-15361	,	_
79-15	15362-15367	clone	_
79-16	15368-15371	7A9	_
79-17	15372-15373	,	_
79-18	15374-15383	Millipore	_
79-19	15384-15385	)	_
79-20	15386-15389	and	_
79-21	15390-15397	β-Actin	_
79-22	15398-15399	(	_
79-23	15400-15408	1:10,000	_
79-24	15409-15410	,	_
79-25	15411-15416	mouse	_
79-26	15417-15418	,	_
79-27	15419-15426	1406030	_
79-28	15427-15428	,	_
79-29	15429-15435	Ambion	_
79-30	15436-15437	)	_
79-31	15438-15447	overnight	_
79-32	15448-15450	at	_
79-33	15451-15454	4°C	_
79-34	15455-15456	.	_

Text=Then, membranes were incubated with the IRDye-labeled secondary antibodies for 45 min at RT in the dark on the rocker.
80-1	15457-15461	Then	_
80-2	15462-15463	,	_
80-3	15464-15473	membranes	_
80-4	15474-15478	were	_
80-5	15479-15488	incubated	_
80-6	15489-15493	with	_
80-7	15494-15497	the	_
80-8	15498-15511	IRDye-labeled	_
80-9	15512-15521	secondary	_
80-10	15522-15532	antibodies	_
80-11	15533-15536	for	_
80-12	15537-15539	45	_
80-13	15540-15543	min	_
80-14	15544-15546	at	_
80-15	15547-15549	RT	_
80-16	15550-15552	in	_
80-17	15553-15556	the	_
80-18	15557-15561	dark	_
80-19	15562-15564	on	_
80-20	15565-15568	the	_
80-21	15569-15575	rocker	_
80-22	15576-15577	.	_

Text=Fluorescence was visualized using a Li-Cor Odyssey Imaging System.
81-1	15578-15590	Fluorescence	_
81-2	15591-15594	was	_
81-3	15595-15605	visualized	_
81-4	15606-15611	using	_
81-5	15612-15613	a	_
81-6	15614-15620	Li-Cor	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
81-7	15621-15628	Odyssey	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
81-8	15629-15636	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
81-9	15637-15643	System	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
81-10	15644-15645	.	_

Text=In vitro transcription and transfection of gRNAs Guide RNAs (gRNAs) were designed on Benchling (www.benchling.com) using the CRISPR tool.
82-1	15646-15648	In	_
82-2	15649-15654	vitro	_
82-3	15655-15668	transcription	_
82-4	15669-15672	and	_
82-5	15673-15685	transfection	_
82-6	15686-15688	of	_
82-7	15689-15694	gRNAs	_
82-8	15695-15700	Guide	_
82-9	15701-15705	RNAs	_
82-10	15706-15707	(	_
82-11	15708-15713	gRNAs	_
82-12	15714-15715	)	_
82-13	15716-15720	were	_
82-14	15721-15729	designed	_
82-15	15730-15732	on	_
82-16	15733-15742	Benchling	_
82-17	15743-15744	(	_
82-18	15745-15762	www.benchling.com	_
82-19	15763-15764	)	_
82-20	15765-15770	using	_
82-21	15771-15774	the	_
82-22	15775-15781	CRISPR	_
82-23	15782-15786	tool	_
82-24	15787-15788	.	_

Text=gRNAs were generated via in vitro transcription (IVT) with the GeneArt Precision gRNA Synthesis Kit (Thermo Fisher Scientific, A29377) as per manufacturer instructions.
83-1	15789-15794	gRNAs	_
83-2	15795-15799	were	_
83-3	15800-15809	generated	_
83-4	15810-15813	via	_
83-5	15814-15816	in	_
83-6	15817-15822	vitro	_
83-7	15823-15836	transcription	_
83-8	15837-15838	(	_
83-9	15839-15842	IVT	_
83-10	15843-15844	)	_
83-11	15845-15849	with	_
83-12	15850-15853	the	_
83-13	15854-15861	GeneArt	_
83-14	15862-15871	Precision	_
83-15	15872-15876	gRNA	_
83-16	15877-15886	Synthesis	_
83-17	15887-15890	Kit	_
83-18	15891-15892	(	_
83-19	15893-15899	Thermo	_
83-20	15900-15906	Fisher	_
83-21	15907-15917	Scientific	_
83-22	15918-15919	,	_
83-23	15920-15926	A29377	_
83-24	15927-15928	)	_
83-25	15929-15931	as	_
83-26	15932-15935	per	_
83-27	15936-15948	manufacturer	_
83-28	15949-15961	instructions	_
83-29	15962-15963	.	_

Text=Five gRNAs were designed per condition (i.e., “ loop-SNP ”, negative control, and positive control) and pooled for transfection.
84-1	15964-15968	Five	_
84-2	15969-15974	gRNAs	_
84-3	15975-15979	were	_
84-4	15980-15988	designed	_
84-5	15989-15992	per	_
84-6	15993-16002	condition	_
84-7	16003-16004	(	_
84-8	16005-16009	i.e.	_
84-9	16010-16011	,	_
84-10	16012-16013	“	_
84-11	16014-16022	loop-SNP	_
84-12	16023-16024	”	_
84-13	16025-16026	,	_
84-14	16027-16035	negative	_
84-15	16036-16043	control	_
84-16	16044-16045	,	_
84-17	16046-16049	and	_
84-18	16050-16058	positive	_
84-19	16059-16066	control	_
84-20	16067-16068	)	_
84-21	16069-16072	and	_
84-22	16073-16079	pooled	_
84-23	16080-16083	for	_
84-24	16084-16096	transfection	_
84-25	16097-16098	.	_

Text=The genomic ranges within which loop-SNP gRNAs were designed (i.e., region spanning the SNP of interest and all gRNAs in the condition) were roughly 600 bp for ASCL1, 550 bp for MATR3, 460 bp for EFNB1 (with 2/5 gRNAs directly overlapping the SNP), 300 bp for SOX2.
85-1	16099-16102	The	_
85-2	16103-16110	genomic	_
85-3	16111-16117	ranges	_
85-4	16118-16124	within	_
85-5	16125-16130	which	_
85-6	16131-16139	loop-SNP	_
85-7	16140-16145	gRNAs	_
85-8	16146-16150	were	_
85-9	16151-16159	designed	_
85-10	16160-16161	(	_
85-11	16162-16166	i.e.	_
85-12	16167-16168	,	_
85-13	16169-16175	region	_
85-14	16176-16184	spanning	_
85-15	16185-16188	the	_
85-16	16189-16192	SNP	_
85-17	16193-16195	of	_
85-18	16196-16204	interest	_
85-19	16205-16208	and	_
85-20	16209-16212	all	_
85-21	16213-16218	gRNAs	_
85-22	16219-16221	in	_
85-23	16222-16225	the	_
85-24	16226-16235	condition	_
85-25	16236-16237	)	_
85-26	16238-16242	were	_
85-27	16243-16250	roughly	_
85-28	16251-16254	600	_
85-29	16255-16257	bp	_
85-30	16258-16261	for	_
85-31	16262-16267	ASCL1	_
85-32	16268-16269	,	_
85-33	16270-16273	550	_
85-34	16274-16276	bp	_
85-35	16277-16280	for	_
85-36	16281-16286	MATR3	_
85-37	16287-16288	,	_
85-38	16289-16292	460	_
85-39	16293-16295	bp	_
85-40	16296-16299	for	_
85-41	16300-16305	EFNB1	_
85-42	16306-16307	(	_
85-43	16308-16312	with	_
85-44	16313-16316	2/5	_
85-45	16317-16322	gRNAs	_
85-46	16323-16331	directly	_
85-47	16332-16343	overlapping	_
85-48	16344-16347	the	_
85-49	16348-16351	SNP	_
85-50	16352-16353	)	_
85-51	16354-16355	,	_
85-52	16356-16359	300	_
85-53	16360-16362	bp	_
85-54	16363-16366	for	_
85-55	16367-16371	SOX2	_
85-56	16372-16373	.	_

Text=Puromycin-selected (1μg/mL in NPC media; Sigma, #P7255) dCas9-VP64 and dCas9-VPR NPCs were seeded at a density of ~400,000 per well on Matrigel-coated (BD Biosciences) 24-well plates.
86-1	16374-16392	Puromycin-selected	_
86-2	16393-16394	(	_
86-3	16395-16401	1μg/mL	_
86-4	16402-16404	in	_
86-5	16405-16408	NPC	_
86-6	16409-16414	media	_
86-7	16415-16416	;	_
86-8	16417-16422	Sigma	_
86-9	16423-16424	,	_
86-10	16425-16426	#	_
86-11	16427-16432	P7255	_
86-12	16433-16434	)	_
86-13	16435-16445	dCas9-VP64	_
86-14	16446-16449	and	_
86-15	16450-16459	dCas9-VPR	_
86-16	16460-16464	NPCs	_
86-17	16465-16469	were	_
86-18	16470-16476	seeded	_
86-19	16477-16479	at	_
86-20	16480-16481	a	_
86-21	16482-16489	density	_
86-22	16490-16492	of	_
86-23	16493-16501	~400,000	_
86-24	16502-16505	per	_
86-25	16506-16510	well	_
86-26	16511-16513	on	_
86-27	16514-16529	Matrigel-coated	_
86-28	16530-16531	(	_
86-29	16532-16534	BD	_
86-30	16535-16546	Biosciences	_
86-31	16547-16548	)	_
86-32	16549-16556	24-well	_
86-33	16557-16563	plates	_
86-34	16564-16565	.	_

Text=Pooled IVT gRNAs (500 ng total RNA/well) and 2 μL EditPro Stem lipofectamine (MTI-GlobalStem, #GST-2174; now, ThermoFisher, STEM00003) were diluted in 50 μL Opti-MEM (Thermo Fisher Scientific, #31985062) and added dropwise to each well.
87-1	16566-16572	Pooled	_
87-2	16573-16576	IVT	_
87-3	16577-16582	gRNAs	_
87-4	16583-16584	(	_
87-5	16585-16588	500	_
87-6	16589-16591	ng	_
87-7	16592-16597	total	_
87-8	16598-16606	RNA/well	_
87-9	16607-16608	)	_
87-10	16609-16612	and	_
87-11	16613-16614	2	_
87-12	16615-16617	μL	_
87-13	16618-16625	EditPro	_
87-14	16626-16630	Stem	_
87-15	16631-16644	lipofectamine	_
87-16	16645-16646	(	_
87-17	16647-16661	MTI-GlobalStem	_
87-18	16662-16663	,	_
87-19	16664-16665	#	_
87-20	16666-16674	GST-2174	_
87-21	16675-16676	;	_
87-22	16677-16680	now	_
87-23	16681-16682	,	_
87-24	16683-16695	ThermoFisher	_
87-25	16696-16697	,	_
87-26	16698-16707	STEM00003	_
87-27	16708-16709	)	_
87-28	16710-16714	were	_
87-29	16715-16722	diluted	_
87-30	16723-16725	in	_
87-31	16726-16728	50	_
87-32	16729-16731	μL	_
87-33	16732-16740	Opti-MEM	_
87-34	16741-16742	(	_
87-35	16743-16749	Thermo	_
87-36	16750-16756	Fisher	_
87-37	16757-16767	Scientific	_
87-38	16768-16769	,	_
87-39	16770-16771	#	_
87-40	16772-16780	31985062	_
87-41	16781-16782	)	_
87-42	16783-16786	and	_
87-43	16787-16792	added	_
87-44	16793-16801	dropwise	_
87-45	16802-16804	to	_
87-46	16805-16809	each	_
87-47	16810-16814	well	_
87-48	16815-16816	.	_

Text=Cells were harvested with TRIzol for total RNA extraction 48 hours later.
88-1	16817-16822	Cells	_
88-2	16823-16827	were	_
88-3	16828-16837	harvested	_
88-4	16838-16842	with	_
88-5	16843-16849	TRIzol	_
88-6	16850-16853	for	_
88-7	16854-16859	total	_
88-8	16860-16863	RNA	_
88-9	16864-16874	extraction	_
88-10	16875-16877	48	_
88-11	16878-16883	hours	_
88-12	16884-16889	later	_
88-13	16890-16891	.	_

Text=All experiments were conducted with 3 to 6 biological replicates from 1 donor (subject S1), generated in parallel, with the donor contributing isogenic dCas9-VP64 and dCas9-VPR effector cells.
89-1	16892-16895	All	_
89-2	16896-16907	experiments	_
89-3	16908-16912	were	_
89-4	16913-16922	conducted	_
89-5	16923-16927	with	_
89-6	16928-16929	3	_
89-7	16930-16932	to	_
89-8	16933-16934	6	_
89-9	16935-16945	biological	_
89-10	16946-16956	replicates	_
89-11	16957-16961	from	_
89-12	16962-16963	1	_
89-13	16964-16969	donor	_
89-14	16970-16971	(	_
89-15	16972-16979	subject	_
89-16	16980-16982	S1	_
89-17	16983-16984	)	_
89-18	16985-16986	,	_
89-19	16987-16996	generated	_
89-20	16997-16999	in	_
89-21	17000-17008	parallel	_
89-22	17009-17010	,	_
89-23	17011-17015	with	_
89-24	17016-17019	the	_
89-25	17020-17025	donor	_
89-26	17026-17038	contributing	_
89-27	17039-17047	isogenic	_
89-28	17048-17058	dCas9-VP64	_
89-29	17059-17062	and	_
89-30	17063-17072	dCas9-VPR	_
89-31	17073-17081	effector	_
89-32	17082-17087	cells	_
89-33	17088-17089	.	_

Text=Each data point in Fig.
90-1	17090-17094	Each	_
90-2	17095-17099	data	_
90-3	17100-17105	point	_
90-4	17106-17108	in	_
90-5	17109-17112	Fig	_
90-6	17113-17114	.	_

Text=2, D to F, represents one biological replicate within each condition.
91-1	17115-17116	2	_
91-2	17117-17118	,	_
91-3	17119-17120	D	_
91-4	17121-17123	to	_
91-5	17124-17125	F	_
91-6	17126-17127	,	_
91-7	17128-17138	represents	_
91-8	17139-17142	one	_
91-9	17143-17153	biological	_
91-10	17154-17163	replicate	_
91-11	17164-17170	within	_
91-12	17171-17175	each	_
91-13	17176-17185	condition	_
91-14	17186-17187	.	_

Text=For each target gene promoter and candidate loop, control gRNAs were strategically placed into the middle third of the (linear) genome portion bypassed by the candidate loop.
92-1	17188-17191	For	_
92-2	17192-17196	each	_
92-3	17197-17203	target	_
92-4	17204-17208	gene	_
92-5	17209-17217	promoter	_
92-6	17218-17221	and	_
92-7	17222-17231	candidate	_
92-8	17232-17236	loop	_
92-9	17237-17238	,	_
92-10	17239-17246	control	_
92-11	17247-17252	gRNAs	_
92-12	17253-17257	were	_
92-13	17258-17271	strategically	_
92-14	17272-17278	placed	_
92-15	17279-17283	into	_
92-16	17284-17287	the	_
92-17	17288-17294	middle	_
92-18	17295-17300	third	_
92-19	17301-17303	of	_
92-20	17304-17307	the	_
92-21	17308-17309	(	_
92-22	17310-17316	linear	_
92-23	17317-17318	)	_
92-24	17319-17325	genome	_
92-25	17326-17333	portion	_
92-26	17334-17342	bypassed	_
92-27	17343-17345	by	_
92-28	17346-17349	the	_
92-29	17350-17359	candidate	_
92-30	17360-17364	loop	_
92-31	17365-17366	.	_

Text=CRISPRa results were analyzed on PRISM with a one-way ANOVA across 3 conditions with a Dunnett ’ s test for multiple comparisons.
93-1	17367-17374	CRISPRa	_
93-2	17375-17382	results	_
93-3	17383-17387	were	_
93-4	17388-17396	analyzed	_
93-5	17397-17399	on	_
93-6	17400-17405	PRISM	_
93-7	17406-17410	with	_
93-8	17411-17412	a	_
93-9	17413-17420	one-way	_
93-10	17421-17426	ANOVA	_
93-11	17427-17433	across	_
93-12	17434-17435	3	_
93-13	17436-17446	conditions	_
93-14	17447-17451	with	_
93-15	17452-17453	a	_
93-16	17454-17461	Dunnett	_
93-17	17462-17463	’	_
93-18	17464-17465	s	_
93-19	17466-17470	test	_
93-20	17471-17474	for	_
93-21	17475-17483	multiple	_
93-22	17484-17495	comparisons	_
93-23	17496-17497	.	_

Text=Cas9 mutagenesis was also performed as described above with the exception of the negative control, which in these experiments consisted of an empty transfection (i.e., lipofectamine + Opti-MEM without any gRNA).
94-1	17498-17502	Cas9	_
94-2	17503-17514	mutagenesis	_
94-3	17515-17518	was	_
94-4	17519-17523	also	_
94-5	17524-17533	performed	_
94-6	17534-17536	as	_
94-7	17537-17546	described	_
94-8	17547-17552	above	_
94-9	17553-17557	with	_
94-10	17558-17561	the	_
94-11	17562-17571	exception	_
94-12	17572-17574	of	_
94-13	17575-17578	the	_
94-14	17579-17587	negative	_
94-15	17588-17595	control	_
94-16	17596-17597	,	_
94-17	17598-17603	which	_
94-18	17604-17606	in	_
94-19	17607-17612	these	_
94-20	17613-17624	experiments	_
94-21	17625-17634	consisted	_
94-22	17635-17637	of	_
94-23	17638-17640	an	_
94-24	17641-17646	empty	_
94-25	17647-17659	transfection	_
94-26	17660-17661	(	_
94-27	17662-17666	i.e.	_
94-28	17667-17668	,	_
94-29	17669-17682	lipofectamine	_
94-30	17683-17684	+	_
94-31	17685-17693	Opti-MEM	_
94-32	17694-17701	without	_
94-33	17702-17705	any	_
94-34	17706-17710	gRNA	_
94-35	17711-17712	)	_
94-36	17713-17714	.	_

Text=Cas9 results were analyzed with an unpaired t test comparing the loop-SNP and negative control conditions.
95-1	17715-17719	Cas9	_
95-2	17720-17727	results	_
95-3	17728-17732	were	_
95-4	17733-17741	analyzed	_
95-5	17742-17746	with	_
95-6	17747-17749	an	_
95-7	17750-17758	unpaired	_
95-8	17759-17760	t	_
95-9	17761-17765	test	_
95-10	17766-17775	comparing	_
95-11	17776-17779	the	_
95-12	17780-17788	loop-SNP	_
95-13	17789-17792	and	_
95-14	17793-17801	negative	_
95-15	17802-17809	control	_
95-16	17810-17820	conditions	_
95-17	17821-17822	.	_

Text=RNA transcriptomic correlation heatmaps Pearson correlation coefficient matrices were calculated for gene expression in the childhood onset schizophrenia data set using R from lists of genes that are located in cell-type-specific loops anchored at schizophrenia risk loci and, as a subset of this list, sets of genes whose proteins participate in an association network for each of the three cell types (see below).
96-1	17823-17826	RNA	_
96-2	17827-17841	transcriptomic	_
96-3	17842-17853	correlation	_
96-4	17854-17862	heatmaps	_
96-5	17863-17870	Pearson	_
96-6	17871-17882	correlation	_
96-7	17883-17894	coefficient	_
96-8	17895-17903	matrices	_
96-9	17904-17908	were	_
96-10	17909-17919	calculated	_
96-11	17920-17923	for	_
96-12	17924-17928	gene	_
96-13	17929-17939	expression	_
96-14	17940-17942	in	_
96-15	17943-17946	the	_
96-16	17947-17956	childhood	_
96-17	17957-17962	onset	_
96-18	17963-17976	schizophrenia	_
96-19	17977-17981	data	_
96-20	17982-17985	set	_
96-21	17986-17991	using	_
96-22	17992-17993	R	_
96-23	17994-17998	from	_
96-24	17999-18004	lists	_
96-25	18005-18007	of	_
96-26	18008-18013	genes	_
96-27	18014-18018	that	_
96-28	18019-18022	are	_
96-29	18023-18030	located	_
96-30	18031-18033	in	_
96-31	18034-18052	cell-type-specific	_
96-32	18053-18058	loops	_
96-33	18059-18067	anchored	_
96-34	18068-18070	at	_
96-35	18071-18084	schizophrenia	_
96-36	18085-18089	risk	_
96-37	18090-18094	loci	_
96-38	18095-18098	and	_
96-39	18099-18100	,	_
96-40	18101-18103	as	_
96-41	18104-18105	a	_
96-42	18106-18112	subset	_
96-43	18113-18115	of	_
96-44	18116-18120	this	_
96-45	18121-18125	list	_
96-46	18126-18127	,	_
96-47	18128-18132	sets	_
96-48	18133-18135	of	_
96-49	18136-18141	genes	_
96-50	18142-18147	whose	_
96-51	18148-18156	proteins	_
96-52	18157-18168	participate	_
96-53	18169-18171	in	_
96-54	18172-18174	an	_
96-55	18175-18186	association	_
96-56	18187-18194	network	_
96-57	18195-18198	for	_
96-58	18199-18203	each	_
96-59	18204-18206	of	_
96-60	18207-18210	the	_
96-61	18211-18216	three	_
96-62	18217-18221	cell	_
96-63	18222-18227	types	_
96-64	18228-18229	(	_
96-65	18230-18233	see	_
96-66	18234-18239	below	_
96-67	18240-18241	)	_
96-68	18242-18243	.	_

Text=Significance was computed calculating the absolute mean correlation coefficient of each correlation matrix (“ organization score ”) as a test statistic against a null distribution generated by random gene sampling.
97-1	18244-18256	Significance	_
97-2	18257-18260	was	_
97-3	18261-18269	computed	_
97-4	18270-18281	calculating	_
97-5	18282-18285	the	_
97-6	18286-18294	absolute	_
97-7	18295-18299	mean	_
97-8	18300-18311	correlation	_
97-9	18312-18323	coefficient	_
97-10	18324-18326	of	_
97-11	18327-18331	each	_
97-12	18332-18343	correlation	_
97-13	18344-18350	matrix	_
97-14	18351-18352	(	_
97-15	18353-18354	“	_
97-16	18355-18367	organization	_
97-17	18368-18373	score	_
97-18	18374-18375	”	_
97-19	18376-18377	)	_
97-20	18378-18380	as	_
97-21	18381-18382	a	_
97-22	18383-18387	test	_
97-23	18388-18397	statistic	_
97-24	18398-18405	against	_
97-25	18406-18407	a	_
97-26	18408-18412	null	_
97-27	18413-18425	distribution	_
97-28	18426-18435	generated	_
97-29	18436-18438	by	_
97-30	18439-18445	random	_
97-31	18446-18450	gene	_
97-32	18451-18459	sampling	_
97-33	18460-18461	.	_

Text=Randomized gene lists were drawn only from the pool of genes with over 1 count per million (CPM) in at least 30% of the experiments described in.
98-1	18462-18472	Randomized	_
98-2	18473-18477	gene	_
98-3	18478-18483	lists	_
98-4	18484-18488	were	_
98-5	18489-18494	drawn	_
98-6	18495-18499	only	_
98-7	18500-18504	from	_
98-8	18505-18508	the	_
98-9	18509-18513	pool	_
98-10	18514-18516	of	_
98-11	18517-18522	genes	_
98-12	18523-18527	with	_
98-13	18528-18532	over	_
98-14	18533-18534	1	_
98-15	18535-18540	count	_
98-16	18541-18544	per	_
98-17	18545-18552	million	_
98-18	18553-18554	(	_
98-19	18555-18558	CPM	_
98-20	18559-18560	)	_
98-21	18561-18563	in	_
98-22	18564-18566	at	_
98-23	18567-18572	least	_
98-24	18573-18575	30	_
98-25	18576-18577	%	_
98-26	18578-18580	of	_
98-27	18581-18584	the	_
98-28	18585-18596	experiments	_
98-29	18597-18606	described	_
98-30	18607-18609	in	_
98-31	18610-18611	.	_

Text=To generate a null distribution of organization scores for a given cell type that accounted for genomic distance and neighborhood effects, we began by randomly selecting a significant PGC interaction for that cell type (e.g., random selection from table S12).
99-1	18612-18614	To	_
99-2	18615-18623	generate	_
99-3	18624-18625	a	_
99-4	18626-18630	null	_
99-5	18631-18643	distribution	_
99-6	18644-18646	of	_
99-7	18647-18659	organization	_
99-8	18660-18666	scores	_
99-9	18667-18670	for	_
99-10	18671-18672	a	_
99-11	18673-18678	given	_
99-12	18679-18683	cell	_
99-13	18684-18688	type	_
99-14	18689-18693	that	_
99-15	18694-18703	accounted	_
99-16	18704-18707	for	_
99-17	18708-18715	genomic	_
99-18	18716-18724	distance	_
99-19	18725-18728	and	_
99-20	18729-18741	neighborhood	_
99-21	18742-18749	effects	_
99-22	18750-18751	,	_
99-23	18752-18754	we	_
99-24	18755-18760	began	_
99-25	18761-18763	by	_
99-26	18764-18772	randomly	_
99-27	18773-18782	selecting	_
99-28	18783-18784	a	_
99-29	18785-18796	significant	_
99-30	18797-18800	PGC	_
99-31	18801-18812	interaction	_
99-32	18813-18816	for	_
99-33	18817-18821	that	_
99-34	18822-18826	cell	_
99-35	18827-18831	type	_
99-36	18832-18833	(	_
99-37	18834-18838	e.g.	_
99-38	18839-18840	,	_
99-39	18841-18847	random	_
99-40	18848-18857	selection	_
99-41	18858-18862	from	_
99-42	18863-18868	table	_
99-43	18869-18872	S12	_
99-44	18873-18874	)	_
99-45	18875-18876	.	_

Text=Using the bp genomic distance of this interaction we randomly selected two 10kb bins from the genome separated by the same distance.
100-1	18877-18882	Using	_
100-2	18883-18886	the	_
100-3	18887-18889	bp	_
100-4	18890-18897	genomic	_
100-5	18898-18906	distance	_
100-6	18907-18909	of	_
100-7	18910-18914	this	_
100-8	18915-18926	interaction	_
100-9	18927-18929	we	_
100-10	18930-18938	randomly	_
100-11	18939-18947	selected	_
100-12	18948-18951	two	_
100-13	18952-18956	10kb	_
100-14	18957-18961	bins	_
100-15	18962-18966	from	_
100-16	18967-18970	the	_
100-17	18971-18977	genome	_
100-18	18978-18987	separated	_
100-19	18988-18990	by	_
100-20	18991-18994	the	_
100-21	18995-18999	same	_
100-22	19000-19008	distance	_
100-23	19009-19010	.	_

Text=All genes overlapping these bins were then added to the list of genes with which to calculate the organization score.
101-1	19011-19014	All	_
101-2	19015-19020	genes	_
101-3	19021-19032	overlapping	_
101-4	19033-19038	these	_
101-5	19039-19043	bins	_
101-6	19044-19048	were	_
101-7	19049-19053	then	_
101-8	19054-19059	added	_
101-9	19060-19062	to	_
101-10	19063-19066	the	_
101-11	19067-19071	list	_
101-12	19072-19074	of	_
101-13	19075-19080	genes	_
101-14	19081-19085	with	_
101-15	19086-19091	which	_
101-16	19092-19094	to	_
101-17	19095-19104	calculate	_
101-18	19105-19108	the	_
101-19	19109-19121	organization	_
101-20	19122-19127	score	_
101-21	19128-19129	.	_

Text=This process was iterated until enough genes were added to the list to match the number of genes used in the original cell-type-specific organization score.
102-1	19130-19134	This	_
102-2	19135-19142	process	_
102-3	19143-19146	was	_
102-4	19147-19155	iterated	_
102-5	19156-19161	until	_
102-6	19162-19168	enough	_
102-7	19169-19174	genes	_
102-8	19175-19179	were	_
102-9	19180-19185	added	_
102-10	19186-19188	to	_
102-11	19189-19192	the	_
102-12	19193-19197	list	_
102-13	19198-19200	to	_
102-14	19201-19206	match	_
102-15	19207-19210	the	_
102-16	19211-19217	number	_
102-17	19218-19220	of	_
102-18	19221-19226	genes	_
102-19	19227-19231	used	_
102-20	19232-19234	in	_
102-21	19235-19238	the	_
102-22	19239-19247	original	_
102-23	19248-19266	cell-type-specific	_
102-24	19267-19279	organization	_
102-25	19280-19285	score	_
102-26	19286-19287	.	_

Text=Finally, this protocol was repeated 1000 times to generate the null distribution of random organization scores.
103-1	19288-19295	Finally	_
103-2	19296-19297	,	_
103-3	19298-19302	this	_
103-4	19303-19311	protocol	_
103-5	19312-19315	was	_
103-6	19316-19324	repeated	_
103-7	19325-19329	1000	_
103-8	19330-19335	times	_
103-9	19336-19338	to	_
103-10	19339-19347	generate	_
103-11	19348-19351	the	_
103-12	19352-19356	null	_
103-13	19357-19369	distribution	_
103-14	19370-19372	of	_
103-15	19373-19379	random	_
103-16	19380-19392	organization	_
103-17	19393-19399	scores	_
103-18	19400-19401	.	_

Text=This distribution was then used to calculate significance of co-regulation (i.e., P = number of times |r|avg of the null exceeded that of the test heatmap / 1000).
104-1	19402-19406	This	_
104-2	19407-19419	distribution	_
104-3	19420-19423	was	_
104-4	19424-19428	then	_
104-5	19429-19433	used	_
104-6	19434-19436	to	_
104-7	19437-19446	calculate	_
104-8	19447-19459	significance	_
104-9	19460-19462	of	_
104-10	19463-19476	co-regulation	_
104-11	19477-19478	(	_
104-12	19479-19483	i.e.	_
104-13	19484-19485	,	_
104-14	19486-19487	P	_
104-15	19488-19489	=	_
104-16	19490-19496	number	_
104-17	19497-19499	of	_
104-18	19500-19505	times	_
104-19	19506-19512	|r|avg	_
104-20	19513-19515	of	_
104-21	19516-19519	the	_
104-22	19520-19524	null	_
104-23	19525-19533	exceeded	_
104-24	19534-19538	that	_
104-25	19539-19541	of	_
104-26	19542-19545	the	_
104-27	19546-19550	test	_
104-28	19551-19558	heatmap	_
104-29	19559-19560	/	_
104-30	19561-19565	1000	_
104-31	19566-19567	)	_
104-32	19568-19569	.	_

Text=Note that STRING gene network transcriptomic analyses (Fig.
105-1	19570-19574	Note	_
105-2	19575-19579	that	_
105-3	19580-19586	STRING	_
105-4	19587-19591	gene	_
105-5	19592-19599	network	_
105-6	19600-19614	transcriptomic	_
105-7	19615-19623	analyses	_
105-8	19624-19625	(	_
105-9	19626-19629	Fig	_
105-10	19630-19631	.	_

Text=4B) were performed with 1000 random permutations of genes sampled from the full schizophrenia risk connectome (i.e., risk locus + risk locus-connect genes) for each cell type.
106-1	19632-19634	4B	_
106-2	19635-19636	)	_
106-3	19637-19641	were	_
106-4	19642-19651	performed	_
106-5	19652-19656	with	_
106-6	19657-19661	1000	_
106-7	19662-19668	random	_
106-8	19669-19681	permutations	_
106-9	19682-19684	of	_
106-10	19685-19690	genes	_
106-11	19691-19698	sampled	_
106-12	19699-19703	from	_
106-13	19704-19707	the	_
106-14	19708-19712	full	_
106-15	19713-19726	schizophrenia	_
106-16	19727-19731	risk	_
106-17	19732-19742	connectome	_
106-18	19743-19744	(	_
106-19	19745-19749	i.e.	_
106-20	19750-19751	,	_
106-21	19752-19756	risk	_
106-22	19757-19762	locus	_
106-23	19763-19764	+	_
106-24	19765-19769	risk	_
106-25	19770-19783	locus-connect	_
106-26	19784-19789	genes	_
106-27	19790-19791	)	_
106-28	19792-19795	for	_
106-29	19796-19800	each	_
106-30	19801-19805	cell	_
106-31	19806-19810	type	_
106-32	19811-19812	.	_

